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Background: Gout is the most common inflammatory arthritis in the U.S., with a prevalence of 
about 3.9%, or 8.3 million individuals. Gout is associated with significant morbidity, functional 
limitation and poor health-related quality of life. In addition, gout has a significant impact on 
economic burden for the U.S. healthcare system (total annual direct medical cost is about $4 
billion). Although the effective treatments are available and the treatment guidelines show the 
clear treatment pathways, the patient adherence to chronic gout treatments is known to be low 
compared with other chronic diseases. Most previous studies have been based on relatively small 
patient populations, so their results are difficult to generalize to the whole U.S. population.  
Objectives: The objectives of this project are to describe and examine factors associated with the 
long-term medication adherence of gout patients in a large sample of the U.S. population. 
Methods: This is a retrospective cohort study using the GE centricity electronic medical record 
(EMR) database. The age, sex and race/ethnics distributions for the data are generally similar to 
that of the overall U.S. population. The primary outcome is patient adherence measured by the 
Medication Possession Ratio (MPR), which is used widely to measure medication adherence for 
chronic disease(s). In addition to adherence measured by the MPR, persistence was studied as the 
second outcome; because the MPR is calculated by the proportion of days during the follow-up 
period in which a patient has available medications, it is difficult to capture the patient’s 
behavior. To understand patient behavior better, persistence was analyzed in addition to 
adherence measured by the MPR.  
Results: The total sample size for this study is 91,629 patients. The sample size of this study is 





was 46.4%. In the adjusted adherence analysis, all 19 covariates (type of medication of Urate-
lowering therapy (ULT), age, gender, race, region, insurance, index year, BMI, CKD stage, 
specialist vs. non-specialist provider classifications, a diagnosis of tophi, a diagnosis of renal 
impairment, serum uric acid measurements (sUA), number of diagnoses of acute gout, 
comorbidities (Charlson Comorbidity Index), the use of NSAIDs, colchicine, or glucocorticoids, 
and heath care utilization) produced statistically significant parameter estimates. The type of 
medication (Febuxostat or Allopurinol) of ULT had the most significant impact on adherence. In 
the unadjusted persistence analysis, 34.8% of patients had a gap between prescriptions that 
qualified as non-persistence. The median time to non-persistence was 1.468 years. In the 
adjusted persistence analysis, 12 of the 19 covariates were statistically significant. 
Conclusions: Type of medication (Febuxostat or Allopurinol) of ULT was one of the most 
critical factors for patient adherence to chronic gout medication. Because Febuxostat is a brand 
medicine whereas Allopurinol is a generic, there is a significant price difference between them, 
which may explain the lower adherence among patients on Febuxostat. Another reason why 
Febuxostat had lower adherence, may be that the treatment induced flares occurred more often 
for those on Febuxostat and patients did not understand the mechanisms inducing the flares at the 
process of ULT. However, because switching between medications cannot be analyzed in this 
study, further study to consider patients’ behavior after switching medicines is needed to reach 
better conclusions regarding the impact of medications on adherence. From the study results and 
the analysis based on the conceptual framework for gout management, 3 possible areas are 
identified for future interventions to improve the adherence: 1) Cost burden mitigation 
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Chapter 1. Introduction/Background  
 
Etiology and Pathology of Gout 
Gout is the common arthritic condition caused by high serum uric acid (sUA) levels, in 
which monosodium urate crystals deposition forms in the joint space, leading to inflammation 
and swelling. [1]  
As Figure 1 shows, gout is mediated by the supersaturation and crystallization of uric acid 
within the joints. The amount of urate in the body depends on the balance between dietary intake, 
synthesis, and excretion. Hyperuricemia results from the overproduction of urate (10%), from 
underexcretion of urate (90%), or often a combination of the two. Approximately one third of 
urate elimination in humans occurs in the gastrointestinal tract, with the remainder excreted in 
the urine. [2] 






Previous studies have indicated a direct positive association between serum urate levels and a 
future risk for gout. [3] [4] The annual incidence of gout was less than 0.1% for men with serum 
uric acid levels less than 416 µmol/L, 0.4% for men with levels of 416 - 475 µmol/L, 0.8% for 
men with levels of 476 - 534 µmol/L, 4.3% for men with levels of 535 - 594 µmol/L, and 7.0% 
for men with levels greater than 595 µmol/L. In Figure 2, the solid line denotes these data points; 
the dotted line shows an exponential projection of the data points. [2] 
Figure 2. The relationship between serum uric acid levels and the incidence of gout [2] 
 
 
Epidemiology and Burden of Gout in the U.S. 
 A study based on the U.S. National Health and Nutrition Examination Survey (NHANES) 
conducted in 2007-2008 found that approximately 8.3 million people (including 6.1 million men 





U.S. adults was 3.9%, the prevalence among men was 5.9% and the prevalence for women was 
2.0%. The prevalence of gout increased with age, with the lowest prevalence (0.4%) in 
individuals ages 20–29 years and the highest prevalence (12.6%) among those ages 80 years or 
older. [5]  
Table 1. Prevalence of gout and number of affected adults in the US, NHANES 2007–2008 [5] 
 
Gout is associated with significant morbidity, functional limitation and health-related quality 
of life (HRQOL) deficits. [6] [7] [8] Lee et al. assessed the impact of gout on HRQOL with the 
Short Form-36 (SF-36) and they found that the gout patients had significantly lower HRQOL 
than the matched general population without gout, for both the Physical Component Summary 





Gout is associated with increased risk for cardiovascular morbidity and mortality. [9] [10] 
[11] Regarding the relationship between hyperuricemia/gout and AMI, Krishnan et al. reported 
that hyperuricemia was associated with a higher risk of acute MI (OR 1.11 [95% CI 1.08–1.15], 
P < 0.001) and that gout was associated with a higher risk of acute MI (OR 1.26 [95% CI 1.14–
1.40], P < 0.001). [9] Also, concerning gout and coronary heart disease (CHD), Choi et al 
reported the multivariate relative risks among men with history of gout were 1.28 (95% 
confidence interval [CI], 1.15 to 1.41) for total mortality, 1.38 (95% CI, 1.15 to 1.66) for CVD 
deaths, and 1.55 (95% CI, 1.24 to 1.93) for fatal CHD, compared with men without history of 
gout and CHD at baseline. [10] Krishnan et al. also reported that gout is associated with 
increased risk for clinical heart failure, subclinical measures of systolic dysfunction and 
mortality. Among their studies, the patients with gout had greater mortality than those without 
(adjusted HR 1.58, 95% CI 1.40 to 1.78). [11] 
In addition to clinical impacts, gout is also associated with a substantial economic burden in 
the U.S. (total annual direct medical costs of about $4 billion), and gout patients with poorly 
controlled sUA levels incur on average higher health care costs than patients whose sUA is better 
controlled. [12] [13] Park et al. reported that gout patients with high levels of sUA had higher 
gout-related health care costs; Mean adjusted gout-related health care costs were $332, $353, and 






Figure 3. Adjusted gout-related health care costs for the 1-year post-index period [12] 
 
 
Management of Gout: Chronic Phase and Acute Phase 
The optimal treatment of gout consists of: 1) adequate chronic use of urate-lowering 
therapies (ULT) aiming to achieve target sUA levels; and 2) anti-inflammatory therapies for 
acute flares and anti-inflammatory prophylaxis during the initial phase of ULT.  [14] [15]  
The American College of Rheumatology (ACR) guidelines recommend a comprehensive 
treatment strategy for management of gout. [Fig 4] At the acute phase with gout flares, treatment 
pharmacologic therapy (NSAIDs, corticosteroids, or colchicine) is recommended to remove pain. 
[Fig 5] Then, for gout attack prophylaxis, it is recommended to initiate low-dose colchicine or 
low-dose NSAIDs when initiating urate-lowering therapy (ULT). Anti-inflammatory prophylaxis 
should be continued from initiation of ULT for the greater of 1) a least 6 months, or 2) following 
achievement of the target serum urate, for 3 months in patients without or 6 months in patients 





used, or if at least one of these is contraindicated or not tolerated, Probenecid can be used to treat 
to the sUA target of <6 mg/dL. sUA should be monitored regularly (every 2-5 weeks) during 
ULT titration, then every 6 months once the target sUA is achieved. [14] 
Adequate lowering of the serum urate (sUA) to a target level of <6.0 mg/dl is associated with 
lower risk of acute flares and better function and quality of life. Thus, achievement of a target 
sUA <6.0 mg/dl with adequate long-term use of ULT is key to quality management of gout.   
Figure 4. American College of Rheumatology Gout Guidelines: Recommendations and Overall Strategic 













Figure 5. ACR Gout Guidelines: Management of Acute Gout Attack [15] 
 
 






Level B Grading  Derived from a single randomized trial or non-randomized studies  
Level C Grading  Consensus opinion of experts, case studies, or standard-of-care  
 
Management of Gout: Treatment Options “Allopurinol or Febuxostat” 
The ACR guidelines recommend Febuxostat or Allopurinol as first line ULT. [14] Allopurinol 
remains the most commonly used medication for the treatment of gout. The recommended 
approach for determining the appropriate dose of allopurinol is to give a starting dose of 100 mg 
daily (and 50 mg/day in stage 4 or worse chronic kidney disease), with further 100-mg increments 
every 2 to 5 weeks until the target level of sUA is achieved. [14] In a retrospective study, it was 
reported that little more than 1/3 of treated patients reached the therapeutic goal of sUA <6 mg/dL 
while on Allopurinol. [16] Although Allopurinol is approved at doses of 100 to 800 mg daily, 95% 
of dosing in the US is at ≤300 mg daily [17]  and many gout patients do not reach the goal serum 
urate range of 300 mg daily. [18] There are several factors contributing to low dosing of allopurinol, 
including intolerance (~10-15%), rare but life-threatening rashes, and hypersensitivity syndrome. 
[19] Dosage reduction is recommended with impaired renal function. [20] 
Febuxostat is a novel nonpurine selective inhibitor of xanthine oxidase indicated for the 
chronic management of hyperuricemia in patients with gout. In randomized controlled trials, the 
efficacy of Febuxostat at 40 mg daily was reported comparable or superior to that of Allopurinol 
at 300 mg once daily, while 80 mg daily of Febuxostat was superior to Allopurinol at 300 mg.[18, 
21, 22] In an open-label extension study it was reported that over 80% of the patients in the 





goal after 1 month of treatment,[23] with no significant difference between the treatment groups 
in the overall reported adverse event rates from any of the trials. [18] [21] [22] [23] Febuxostat 
was also more effective than Allopurinol in a subset of patients with impaired renal function, 
without the need for any dose adjustment in patients with mild-to-moderate renal impairment.[24]  
 
The Purpose and Significance of this Study 
The purpose of this project is to describe and examine factors associated with the long-term 
medication adherence of gout patients in a large sample of the U.S. population. 
As mentioned above, adequate lowering of serum urate (sUA) to a target level of <6.0 mg/dl 
leads to the improvement of patients’ QoL. Compliance of patients with chronic disease 
medications is one of the most important keys for gout management.  
Poor compliance with gout medications has been recognized. Adherence to gout medications 
is remarkably low compared to the medication adherence of those with other chronic conditions. 
(More details about the previous studies will be discussed in the next chapter.)   However, there 
is not enough research which represents the entire general population of patients in the U.S. with 
gout.  Some of the previous studies had relatively large study populations and national coverage, 
but many of them lacked sufficient numbers and coverage to represent the whole U.S. 
population.  As one of the reasons why relatively few studies about gout have been conducted, it 
is possible that people tend to underestimate the impact of gout on patients and society. 
Generally speaking, gout tends to be recognized as a “pain attack which can be treated with OTC 





HRQOL perspectives and the burden on society. To improve the current situation, not only ad 
hoc responses but more root-cause treatment needs to be considered. It is hoped that the study of 
long-term medication adherence of gout patients will contribute to improving the current 
situation. 
There has been no report to date from a gout medication adherence study in the U.S. that 
includes the relatively new treatment, Febuxostat. All of the previous studies reported the patient 
adherence for Allopurinol only because Febuxostat was launched in the U.S. market fairly 
recently (in 2009) and the market share is still not substantial.  Even if the Febuxostat usage is 
not very prevalent, considering the potential effectiveness and benefits to patients, it may be 
meaningful to have a more comprehensive study of current gout medications. Therefore, this 
study of patient adherence, which includes both Allopurinol and Febuxostat with a large database 
covering the entire U.S., can make a meaningful contribution.  
In this study, in addition to the adherence among the whole study population, the comparison 
between Allopurinol and Febuxostat in terms of adherence was also studied. As discussed above, 
Febuxostat is considered to be more effective than existing treatment options and high patients’ 
satisfaction was reported. [25] At the same time, because Febuxostat is a brand medicine, the 
cost burden to patients is considered to be high. So far, there has been no report to compare the 
adherence between these two medications. Although this study has a data limitation regarding 
cost information because EMR data does not have the claims information, it can be considered 






It is critical to understand the factors associated with chronic gout medication adherence to 
develop a plan to improve gout medication adherence. As I discuss in more detail in the literature 
review chapter, there are several key factors which have been considered related to medication 
adherence. For example, the type of prescribers (specialist vs non-specialist) had a significant 
impact on the adherence. This finding implies that physician and patient education may improve 
the outcome. If the related factors are adequately captured through this study, the information 
will be useful to develop the countermeasures to be taken. The positive impact will be brought to 
not only individual patients but also the society through the optimal utilization of medical 
resources and the improved productivity. 
 
The Structure of this Dissertation 
Following this chapter 1, I summarize the previous studies about adherence to chronic gout 
management as the results of the literature review in Chapter 2. From the previous studies’ 
findings, I describe the relationships between outcomes and adherence, adherence in several 
populations, potential factors which have an impact on poor (good) adherence and other factors 
related to adherence in gout management.  
In Chapter 3, I describe the methodology of this study, including the conceptual framework, 
data source, study population, study outcomes, covariates and analytic techniques.  
In Chapter 4, I report all analysis results based on the methods which were described in 





adherence and sub-group analysis results (sub-groups by baseline flares or tophi and by baseline 
NSAIDS, steroids or colchicine). 
In Chapter 5, I develop the discussion of findings from the analysis reported in Chapter 4 and 
present conclusions from this study. I also explore the implications for interventions to improve 
adherence based on this study’s findings. In addition, I state the limitations of this study and 









Chapter 2. Literature Review  
Adherence and outcomes in chronic gout management  
 Several researchers have reported on the relationship between adherence and treatment 
outcomes in chronic gout management. Reach mentioned that poor adherence was the main 
factor limiting the effectiveness of gout treatment in a review of gout treatment in 2011. In this 
review, Reach also pointed out that poor adherence may be caused by the lack of prophylactic 
treatments and poor patient education about treatment-induced flares occurring at the beginning 
of ULT. [26]  
 
Previous studies which reported adherence in chronic gout management  
Several studies have been conducted to clarify the adherence to drug treatments for gout 
management and have pointed out the very low adherence rates. So far, all of the past research 
studies about chronic gout management in the U.S. have studied the adherence to Allopurinol 
only; no study has been conducted about the adherence to Febuxostat. 
The following table summarizes the adherence data from previous studies about chronic 
gout management. A summary and discussion about each study follows. 
Basically, all identified previous studies used the Medication Possession Ratio (MPR) to 
measure adherence. (Riedel. et al. used a different name in their report, but its calculation 
method is the same as the methods of MPR calculation. [27] The author was contacted and it was 
confirmed that it’s identical with MPR.) An MPR of 80% (0.8) has been widely used as the 





identified studies that reported adherence in chronic gout management also used this threshold. 
[28] [29]  
 
Table 2. Adherence data from past studies about chronic gout management 
Author Number of 
patients 
Study population MPR>80% Note 
Briesacher et 
al. (2008)[30] 
9715 US population  
>18-year-old patients 
who had diagnosis of 
gout during study 
period 2001-2004 
36.8% Comparison of drug 
adherence among 
patients with 7 
different conditions  
Riedel et al. 
(2004) 
[27] 
5597 US population 
Gout patients who 






Sarawate et al. 
(2006)[17] 






Harrold et al. 
(2008) [31] 










Solomon et al. 
(2008) [32] 
9823 US population  
>65-year-old patients 
enrolled in pharmacy 
benefit program 
36%  
Halpern et al. 
(2009) [33] 





Goddard et al. 
(2013) [34] 
7644 Israeli population 
>25 year--old 
patients 
with the diagnosis of 
gout treated with 
allopurinol identified 





Briesacher et al. (2008) using MPRs, compared the chronic medication adherence among 
patients with gout, hypercholesterolemia, hypertension, hypothyroidism, osteoporosis, seizure 
disorders, and type 2 diabetes mellitus. The medication adherence among gout patients was the 






Figure 6. Comparison of drug adherence rates across seven medical conditions. [30] 
 
For patients with gout, MPRs increased with increasing comorbidities. Those with low 
comorbidity had a mean MPR of 52.3% (95% CI 51.4–53.3%), whereas those with high 
comorbidity had a mean MPR of 62.2% (95% CI 60.4–64.1%). 
 
Riedel et al. (2004) examined compliance with allopurinol therapy among managed care 
enrollees with gout. They reported the lowest adherence rate (18%) among the several studies of 
gout medication adherence. In their study, the compliance with allopurinol was analyzed for 
5597 subjects who filled at least 2 prescriptions for allopurinol. They reported that male gender 
was associated with decreased compliance, although the effect of gender diminished with 
increasing age. Increased compliance was associated with increasing age in both sexes and with 





long compared with other studies. It may be one explanation for their findings about the low 
adherence rate. 
 
Sarawate et al. (2008) found low compliance with allopurinol as a medication for gout. 
They concluded that patients may receive suboptimal quality of care as measured by serum urate 
testing, and as measured by appropriate dosing of Allopurinol for those patients with renal 
impairment. In their study, 64.9% of allopurinol users had a modal daily dose or the most 
commonly observed daily dose of 300 mg/d, the median length of therapy was 3 months, and a 
high proportion of patients had a medication possession ratio of 10% or less. They found that 
53% of patients with renal impairment received a modal daily dose of 300 mg or greater, and 
83% of patients who started taking allopurinol did not have their serum urate levels measured 
within 180 days. They reported that patients with gout flares were less likely to be compliant 
with allopurinol (odds ratio, 0.50; 95% confidence interval,0.40-0.63) and patients with renal 
impairment at baseline were 3.2 times more likely to undergo serum urate testing than patients 
without renal impairment (odds ratio, 3.20; 95% confidence interval, 1.25-8.23). [17] 
 
Harrold et al. (2009) reported 44% of their study population achieving an MPR > 0.80. 
The predictors of non-adherence included age less than 50 years, fewer comorbid conditions 
based on the Charlson score, no provider visits specifically for gout care prior to ULT initiation, 
and the use of NSAIDs in the year prior to ULT initiation.  As other studies have suggested, they 
reported that younger and healthier patients with gout have a tendency toward lower adherence. 
They pointed out that this pattern may be related to lack of knowledge among patients with gout 





prior to ULT initiation was associated with non-adherence and pointed out the possibility that a 
face-to-face meeting focused on gout is needed to discuss the rationale and goals of medication 
treatment of gout. [31] 
Solomon et al. (2008) assessed adherence with ULT over a 1-year study period among 
9823 older patients (65 years old or older) and found poor adherence (36%) as other studies have 
reported. They reported that predictors of poor adherence included younger age (odds ratio (OR) 
1.50, 95% CI 1.33–1.69 for ages 65–74 compared with 85 and above) and African–American 
race (OR 1.86, 95% CI 1.52–2.27 compared with Caucasian race). An interesting point of this 
study is that they found that treatment by non-specialists may be related to the poor adherence. 
Most patients (93%) received their initial ULT prescription from a non-specialist and this also 
predicted poor adherence (OR 1.15, 95% CI 0.96–1.38 compared with treatment by 





Table 3. Adjusted logistic regression models for non-adherence; variables associated with less than 80% 
of days covered [32] 
 
They also developed a plot of the survival distribution of the time until an extended break 
occurred for all patients. It shows that about one-quarter of patients have an extended break in 
treatment after their first prescription and by 365 days, more than half have had an extended 





Figure 7. Plot of the proportion of patients who remained adherent (y-axis) with uric acid lowering 
therapy (UALT) as a function of duration since first prescription (x-axis). 
 
 
Halpern et al. (2009) studied the relationships among Allopurinol compliance, sUA 
levels, and healthcare expenditures associated with gout. In their study, 44% of the 10070 
patients with at least one Allopurinol prescription filled were compliant with an MPR >80%. 
[33]  
They reported a strong association between medication compliance and sUA level. Unadjusted 
comparisons of allopurinol compliance by post-allopurinol sUA level showed a consistent 
association between compliance and sUA < 6.0 mg/dL. Among subjects with a sUA result 30–89 
days after the first allopurinol fill, 49.3% of compliant users had sUA < 6.0 mg/dL compared 
with 27.8% of non-compliant users (p < 0.001). Among subjects with a sUA result in the 90–149 
day period, 51.8% of compliant users had sUA < 6.0 mg/dL compared with 22.5% of non-
compliant allopurinol users (p < 0.001). And among subjects with a sUA after 150 days, 56.8% 
versus 23.8% of compliant and non-compliant allopurinol users, respectively, had 
sUA < 6.0 mg/dL (p < 0.001). The findings support the importance of adherence improvement in 





Figure 8. Allopurinol compliance and serum uric acid <6.0 mg/dL [33] 
 
   
 Zandman-Goddard et al. (2013) studied 7644 patients in Israel and found only 17% of the 
study population were adherent to allopurinol therapy. Similar to previous studies, they found 
age and comorbidities are related to medication adherence. (Patients who were young upon 
initiation of allopurinol therapy were more prone to treatment discontinuation and people with 
other chronic disorders, in particular cardiovascular diseases, were found to be more compliant. 
They also pointed out that high flare rates may contribute to a loss of confidence in the benefit of 
the medication and may lead to subsequent poor adherence. [34] 
 







Potential factors associated with adherence in chronic gout management  
Lack of knowledge/patient education 
 As mentioned above, in a review of gout treatment Reach pointed out that poor adherence 
may be caused by poor patient education about treatment-induced flares occurring at the 
beginning of ULT. [26] At the onset of ULT, decreasing the sUA level by treatment may trigger 
the acute gout flares. It is known as the treatment-induced flare. According to Becker et al., the 
lowering of serum urate may cause the change in urate concentrations and trigger the flares. [35]  
Sometimes, patients misunderstand and believe that the further gout attack means the treatment 
is not working and stop taking the medicine, if they did not receive the adequate explanation 
before starting the ULT regarding possible flares just after the onset of treatment. 
 Harrold et al. also reported that the lack of provider visits associated with a gout 
diagnosis prior to ULT initiation was associated with non-adherence; they remarked that possibly 
a face-to-face meeting focused on gout is needed to discuss the rationale and goals of medication 
treatment of gout. [29] 
 
Specialist vs Non-specialist 
 Beyond the challenge of patient education, the underlying root cause of lack of patient 
education might be a lack of knowledge and low adherence to the standard treatment guidelines 
among physicians.  
 Solomon et al. reported that a prescription from a non-specialist was one of the predictors 
of poor adherence to gout treatments. In their study, most patients (93%) received their initial 





0.96-1.38) compared with receiving prescriptions from specialists (rheumatologists or 
nephrologists).   
Odera et al. pointed out that there is room to improve the physicians’ treatment 
compliance with ACR guidelines among both primary care physicians (PCPs) and 
rheumatologists. Although both specialists and PCPs have room to improve, they reported that 
PCPs are less compliant with the treatment guidelines than rheumatologists. [36] 
  
Patients’ health status (with/without chronic disease) 
Briesacher et al. reported that adherence was increased with the increase of comorbidity 
burden. They reported that this trend was found also for other chronic diseases (hypertension, 
hypercholesterolemia). [30] Riedel et al. reported that the increasing compliance was associated 
with the presence of diabetes or hypertension. [27] Zandman-Goddard, G., et al. also reported 
better compliance among those with comorbidities, particularly among patients with concomitant 
cardiovascular disease. [34] 
Patients with other chronic diseases may have the custom to take medicines as part of 
their routines in everyday life. It may also be considered that patients with other comorbidities 
may tend to be concerned about their own health, which leads to the better adherence to gout 
treatments.  
 
Patients’ age and gender 
 Many researchers have reported that younger age was associated with the lower 





Riedel et al. reported that male gender was associated with decreased compliance, 
although the effect of gender diminished with increasing age and that increased compliance was 
associated with increasing age in both sexes. [27] 
 
Other factors (marital status, socioeconomic status, BMI, race) 
 Zandman-Goddard et al. reported that non-married individuals, those of low 
socioeconomic status and those with lower BMI were associated with lower adherence. [34] 
Solomon et al. reported that African-American race was one of the predictors of poor adherence 
to gout treatments. (Solomon’s study did not control for socioeconomic status.) [32] 
The finding about the relationship between lower BMI and poor adherence is considered to 
be aligned with other findings that healthier patients are less adherent to gout treatments. Lower 
SES also may be a critical factor contributing to adherence to gout treatments. As I discussed 
above, gout sometimes is recognized as “just a pain that can be treated with cheap OTCs” among 
the general population. Considering this fact, those with lower SES may prefer to skip gout 






Chapter 3. Methods  
Conceptual Framework 
To understand the mechanisms of medication adherence to gout management, the following 
conceptual framework was developed based on the conceptual framework used in a study of 
medication use among older adults (Age ≥50 years) by Murray et al. [37] and the findings from 
previous gout adherence studies. 
Based on the conceptual framework by Murray et al. [37], there are 3 environment factors: 1) 
External Environment (e.g. Living conditions, Community environment, Weather), 2) Healthcare 
System (e.g. Availability of Medical Care, Policy, Insurance), and 3) Medication Use System 
(e.g. Reminder system.)  
Regarding patient characteristics, there are also 3 factors: 1) Predisposing characteristics (e.g. 
sex, age, knowledge of disease, attitude to treatment), 2) enabling resources (e.g. insurance, 
money, transportation to pharmacy), and 3) Need factors (e.g. Number of flares, Tophi). Along 
with the conceptual framework used in the medication study by Murray et al. [37], the findings 
from previous gout studies which were discussed in Chapter 2 and are shown in  Table 4 were 








Table 4. Summary of findings from previous studies 
Author Covariates Findings Note 
Briesacher et 
al. (2008) 
age, sex, geographic residence, history of drug, 
type of health plan, and a comorbidity score calculated by 
using the Hierarchical Condition 
Categories risk adjuster 
MPRs increased with increasing 
comorbidities and ages. 
History of drug use, health plan, 
the subject’s geographic 
area of residence, or Sex did not 
influence adherence. 
Comparison of drug 
adherence among 
patients with 7 
different conditions. 
No Lab data 
Riedel et al. 
(2004) 
sex, age, prescription filled, comorbidity (diabetes, 
hypertension, Renal failure, Obesity, RA, Depression, OA) 
Sex (female has better 
compliance), Age, Diabetes and 
hypertension are associated with 
increased compliance. 
No Lab data 
Sarawate et al. 
(2006) 
age, sex, preindex comorbidities, newly or previously 
diagnosed 
gout, and gout flare before postindex serum urate 
testing 
Patients with a gout flare before 
postindex serum urate 
testing were 50% less likely to be 
compliant. 
Patients with baseline 
hypertension were 44% more 
likely to be compliant. 
No Lab data 
Harrold et al. 
(2008) 
age, sex, health care utilization (visits to providers for gout 
both prior to and after ULD initiation, all provider visits 
prior to ULD initiation, and number of hospitalizations 
prior to ULD initiation), specific comorbidities, 
medications. 
Predictors of poor adherence 
included younger age, 
fewer comorbid conditions, no 
provider visits for gout prior to 
urate-lowering drug initiation, and 
use of NSAID prior to urate-
lowering drug initiation 
No Lab data 
Solomon et al. 
(2008)  
age, gender, race), medical care intensity (number of 
physician visits, number of different medications used, 
number of acute care hospitalisations), comorbid 
conditions, gout specific 
factors (the number of acute gout arthritis diagnoses; a 
diagnoses of nephrolithiasis; a diagnosis of tophi; a 
diagnosis of interstitial nephritis; the use of selective or 
non-selective  NSAID, colchicine, or glucocorticoids and 
uric acid measurements), and physician characteristics 
(specialist or not) 
Predictors of poor adherence 
included younger age, African–
American race and prescription 
from non-specialist physicians. 
No Lab data 
Halpern et al. 
(2009)  
sUA Compliance was positively 
associated with favorable sUA in 
unadjusted comparisons. 
Lab data (sUA only) - 
no other covariates 
Zandman-
Goddard et al. 
(2013)  
age, sex, marital status, place of residency, years of stay in 
Israel, socio-economic level, chronic conditions, BMI, 
smoking 
Women aged 45-64 years, non-
married individuals, those of low 
socioeconomic status and those 
with lower BMI were more likely 
to discontinue therapy. 
Better compliance was achieved 








The factors in green boxes in Figure 9 show those variables which are related to adherence in 
the previous studies. The factors in orange boxes in Figure 10 are those identified for the 
possible related factors in this study. After the analysis, future possible interventions are 
considered based on the findings. 
 
Figure 9 Conceptual Framework of Gout Medication Adherence with the factors which are related to 








Figure 10 Conceptual Framework of Gout Medication Adherence with the factors which a which are 




 This is a retrospective cohort study using the GE centricity electronic medical 
record (EMR) database. The data for the time period of January 1, 2009 through 
December 31, 2014 were used for this analysis. The GE centricity EMR database consists 
of longitudinal ambulatory electronic health data covering over 38 million U.S. patients 
in 49 states and Washington, D.C. The database contains patient information on 
demographics, laboratory test results, medication lists, prescriptions, and payment types. 
The GE Centricity EMR database captures patient-level clinical data elements obtained 





The Centricity ambulatory care EMR and its predecessors have been used for over 20 
years, are certified by the Certification Commission for Healthcare Information 
Technology (CCHIT), and were used by over 30,000 clinicians in the United States in 
2009. Centricity CDS includes data provided by 7259 clinicians (including approximately 
60% primary care providers and 40% specialists) at 98 installations with 133 unique 
provider members. CDS includes de-identified, standardized data on more than 8,900,000 
patients; and the data on at least half of these patients spans more than 985 days, for a 
median of approximately 2.7 years of continuous care. [38] 
One study assessed the external validity and generalizability of the GE Centricity EMR 
database and analytical results to the US population using the National Ambulatory 
Medical Care Survey (NAMCS) data, the distributions of demographics in the GE 
Centricity EMR database were found to be generally similar to that of the overall U.S. 
population as captured in the NAMCS data, although the GE Centricity EMR database 
shows higher proportions of visits by younger patients and by females.[38] 
 All study data were de-identified and compliant with the Health Insurance 
Portability and Accountability Act (passed by the U.S. Congress in 1996.) The JHSPH 
IRB reviewed the application for this study on May 6, 2015 and determined that the 
proposed activity described in the application would use de-identified existing data to 
examine medication adherence to Febuxostat/allopurinol among gout patients. Therefore, 
they concluded that this study did not qualify as human subjects research as defined by 








The analyses for this study were generated using SAS software Ver 9.4. 
Copyright, SAS Institute Inc. SAS and all other SAS Institute Inc. product or service 
names are registered trademarks or trademarks of SAS Institute Inc., Cary, NC, USA. 
 
Study Population 
This study cohort included gout patients who received urate-lowering therapy 
(ULT) between January 1, 2009 and December 31, 2014. Subjects were included in the 
analysis if they met the following criteria: 1) Adult patients, ≥18 years of age at index 
date, 2) Diagnosed with gout (ICD-9, 274.xx) any time before (or on) the index date, 3) 
Newly treated with Allopurinol or Febuxostat on or after January 1, 2009, and 4) had 
continuous database activity for at least 6 months pre-index date (baseline period) and 6 
months post-index date. The patients who used Allopurinol or Febuxostat at the baseline 






Table 5. Inclusion and Exclusion Criteria 
Inclusion Criteria Exclusion Criteria 
1. Adult patients, ≥18 years of age at 
index date 
2. Diagnosed with gout (ICD-9, 
274.xx) any time before (or on) 
the index date,  
3. Newly treated with Allopurinol or 
Febuxostat on or after January 1, 
2009,  
4. Patients had continuous database 
activity (defined by flag of patient 
status in database) for at least 6 
months pre-index date (baseline 
period) and 6 months post-index 
date. 
1. The patients who used 
Allopurinol or Febuxostat at the 6 
months pre-index date (baseline 
period) were excluded. 
 
The follow-up period ends on the last day of continuous database activity for any 
individual patient or December 31, 2014. The last day of continuous database activity 
will mark the end of follow-up. Censoring for the persistence measure is described in 





Figure 11. The study period: Censoring for the persistence measure   
 
In this study, the switching between medications was not studied because of the 
data limitations.  
 
Study Outcomes 
Primary outcome: Adherence measured by Medication Possession Ratio (MPR) 
In this study, adherence to ULT medication was measured by the Medication 
Possession Ratio (MPR), which is used widely to measure medication adherence for 





of medication dispensed (excluding the last refill) divided by the number of days between 
the first and last prescription refill. [40] 
 𝑀𝑃𝑅 =
The days supply of medication dispensed in period
 Last prescription fill date−First fill date+Last fill days supply
 
As discussed in Chapter 2, an MPR of 80% (0.8) has been widely used as the 
threshold for good/poor adherence in a variety of studies covering many therapeutic 
areas. In addition, the previous studies that reported adherence in chronic gout 
management (Briesacher et al. (2008), Riedel et al. (2004), Sarawate et al. (2006), 
Harrold et al. (2008), Solomon et al. (2008), Halpern et al. (2009), Zandman-Goddard et 
al. (2013) ) also used this threshold.    
Secondary outcome: Persistence 
Persistence with ULTs was assessed as the time from the Index date until an 
extended break in treatment, defined as the first prescription gap of at least 60 days.  
𝑃𝑒𝑟𝑠𝑖𝑠𝑡𝑒𝑛𝑐𝑒 = 𝐷𝑎𝑦𝑠 (𝑌𝑒𝑎𝑟𝑠) 𝑡𝑎𝑘𝑖𝑛𝑔 𝑚𝑒𝑑𝑖𝑐𝑎𝑡𝑖𝑜𝑛𝑠 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑒𝑥𝑐𝑒𝑒𝑑𝑖𝑛𝑔 𝑎 60 𝑑𝑎𝑦𝑠 𝑔𝑎𝑝 
Because MPR is calculated by the proportion of days during the follow-up period 
in which a patient has available medications, it is difficult to assess the patient’s behavior. 
To understand more about patient behavior, persistence was analyzed in addition to 
adherence measured by the MPR. A similar analysis was conducted by Solomon et al. 
with their study population (more than 65 years old patients who enrolled in a pharmacy 
benefit program). This study follows the approach used by Solomon, et al.  The 





Medication Compliance and Persistence Work Group (Cramer et al.) defined medication 
adherence (compliance) as “the extent to which a patient acts in accordance with the 
prescribed interval, and dose of a dosing regimen” and medication persistence as “the 
duration of time from initiation to discontinuation of therapy.” They pointed out that 
clinical outcomes of treatment are affected not only by how well patients take their 
medications but also by how long they take their medications and conclude that both 
sides should be considered to capture the comprehensive behavior. [41] 
Figure 12. Definitions of compliance and persistence by Caramer et al. [41] 
 
Leppe et al. also reported that the combination of an MPR and a persistency 







Covariates (Potential Confounding Factors): 
Covariates included the type of medication (Febuxostat or Allopurinol) of ULT,  
demographics (age, gender, race, region), insurance plan, Index year, body mass index 
(BMI), CKD stage defined by estimated glomerular filtration rate (eGFR), specialist 
(Rheumatologist / Nephrologist)  vs. non-specialist provider classifications, a diagnosis 
of tophi, a diagnosis of renal impairment, serum uric acid measurements (sUA), number 
of diagnoses of acute gout arthritis (gout flares, separated from each other by at least 30 
days), comorbidities (quantified with the Charlson Comorbidity Index (CCI)), the use of 
NSAIDs, colchicine, or glucocorticoids and uric acid measurements (sUA)), and heath 
care utilization (number of different types of medications used during baseline) 
Table 6. List of Covariates 
Covariates Short Name Value Note 
Febuxostat vs 
Allopurinol 
FEBUX 1 (Febuxostat), 0 (Allopurinol)   
Age AGE 18-44,45-64,65+ Adult patients (Age >18) 
Gender GEN Male, Female, Missing  
Race ETHN Asian, Black, Hispanic, White, 
Other, Unknown 
 
Region REG Northeast, Midwest, South, 
West 
 
Insurance INSU Commercial, Medicare, Other, 
Unknown 
 
Index year INDEX 2009, 2010, 2011, 2012, 2013, 
2014 
 
BMI BMI Underweight, Normal weight, 
Pre-Obese, Obese 
BMI values were used to 
classify patients as follows- 
underweight (BMI<18.5 
kg/m2), normal weight 
(18.5-24.9 kg/m2), pre-
obese (25.0-29.9 kg/m2), 





Covariates Short Name Value Note 
CKD stage CKDSTG Stage 1 (eGFR ≥ 90), Stage 2 
(GFR 60-89), Stage 3 (GFR 30-
59), Stage 4 (eGFR < 30) 
The following equation 
was used to compute 
eGFR: GFR (mL/min/1.73 
m2) = 175 × (serum 
creatinine level)-1.154 × 
(Age)-0.203 × (0.742 if 






SPEC 1 (Specialist), 0 (Non-specialist) Specialist:  Rheumatologist 
and Nephrologist 
Diagnosis of gout 
tophi 
TOPHI 1 (Tophi), 0 (No tophi) Tophi - 274.03 tophus, 
274.81 ear, 274.82 non-ear, 
subset of gout (274.xx) 
Diagnosis of renal 
impairment 




Serum uric acid 
measurements 
(sUA) 
SUA sUA < 6mg/dL, 6-6.99mg/dL, 




diagnoses of acute 
gout arthritis (gout 
flares, separated 
from each other 
by at least 30 days 
FLARE 0, 1, 2-3 Gout flares 274.xx with 
NSAID, colchicine, 
glucocorticoids or joint 
aspiration/drainage within 
7 days, OR 719.4x with 
colchicine within 7 days (≥ 






CCI 0, 1, 2, 3 Comorbidities were 
quantified with the 
Charlson Comorbidity 
Index (CCI) using ICD-9 
codes captured within the 
6-month baseline period. 
Use of NSAIDs NSAID 1 (Use of NSAIDs), 0 (No Use 
of NSAIDs) 
 
Use of colchicines Colchicine 1 (Use of colchicines), 0 (No 




Steroid 1 (Use of glucocorticoids), 0 





different types of 
medications used 
during baseline) 





 Age groups included 18-44, 45-64 and 65 and over, based on the advice from Dr. 
Choi, an author of The American College of Rheumatology (ACR) Guidelines on the 
Management of Gout. Also, these are aligned with the age categories used in previous 
studies. 
The Charlson Comorbidity Index (CCI) was used to quantify and consider the 
adjustment for comorbidities in this model. Although there exist newer models for the 
adjustment of comorbidities such as the Elixhauser approach, and there are discussions 
regarding which comorbidity model is the best approach for the database analysis [42], 
considering the comparability with the previous studies, I decided to use the CCI. All past 
studies which adjusted for comorbidities used the CCI. 
 
Medications in the model list were as follows:  
• Medication list 
o Febuxostat (Brand name Uloric): GPI_CATEGORY_4 = ‘FEBUXOSTAT’ 
o Allopurinol (Generic): GPI_CATEGORY_4 = ‘ALLOPURINOL’ or 
‘ALLOPURINOL SODIUM’ 
o Colchicine (Colcrys): GPI_CATEGORY_4 = ‘COLCHICINE’ 
o NSAID: GPI_CATEGORY_2 = ‘NONSTEROIDAL ANTI-
INFLAMMATORY AGENTS (NSAIDS)’ 






ICD-9 codes used in the model were as follows:  
• Disease endpoint ICD-9 codes 
o Tophi - 274.03 tophus, 274.81 ear, 274.82 non-ear, subset of gout (274.xx) 
o Gout flares 274.xx with NSAID, colchicine, glucocorticoids or joint 
aspiration/drainage within 7 days, OR 719.4x with colchicine within 7 days (≥ 
30 days apart) 
o Renal impairment 580.xx‒586.xx. 
 
Analytic Techniques 
First, the baseline characteristics of the study population were examined for the 
whole study population and with a breakdown by medication.  
Second, the MPR was used to estimate adherence and was examined for the 
whole study population and with a breakdown by medication. At first, the unadjusted 
MPR was calculated and examined by medication. Next, the MPR was used as the 
response in a logistic regression model with all covariates included in the model. When 
conducting a logistic regression model, it was defined that < 80% was considered poor 
adherence which is aligned with the definitions of previous studies. Initially, all 
covariates were considered potentially important and entered in the model. Variables 





selection algorithm was used, and covariates with a p-value below 0.05 were retained in 
the model along with the indicator of Febuxostat. In the results all 19 covariates produced 
significant parameter estimates (p-values below 0.05.) The odds ratios and corresponding 
95% confidence intervals for all significant covariates were reported.  
  
 
In addition, one-year adherence, truncating the follow-up at one year, was also 
calculated. 
Then persistence of use was examined using Kaplan–Meier survival plots. Similar 
to the adherence analysis described above, at first, the unadjusted persistence was 
calculated and examined by medication. A Cox regression was fitted in the same manner 
as the MPR model above. A stepwise selection algorithm was applied to all the variables, 
and covariates with p-values below 0.05 were retained in the model along with the 
indicator of Febuxostat. As a result, 12 of the 19 available covariates were retained. More 
details of the stepwise process will be described in the results section. The hazard ratios 









In addition to the adherence and persistence analysis with the whole population, 
two subgroups were analyzed in terms of their unadjusted adherence and persistence, as 
well as their adjusted adherence: (i) patients who had tophi or at least one flare at 
baseline, and (ii) patients who were prescribed NSAIDs, steroids or colchicine at 
baseline. I conducted these sub analyses to examine: 1) the population with more severe 
gout (patients who had tophi or at least one flare at baseline are considered to be more 
severe gout patients) and 2) the patients with prophylaxis (NSAIDs, steroids or colchicine 
at baseline can be considered as prophylaxis to prevent gout flares).  
The rationale is that the severity of disease status and prophylaxis might have 
major impacts on medication adherence based on the results from previous studies.  
Prophylaxis can prevent the treatment induced flares which are considered as a potential 
reason why patients stop taking medicine. These factors are included as covariates in the 
adjusted analysis, however it is considered to be meaningful to understand the patient 
behavior of the population who might have higher medical needs and those who might 





Chapter 4. Results  
Study Population 
Figure 13 displays the whole study population. The total sample size for this study 
is 91,629 patients. The sample size of this study is much larger than those of previous 
studies which analyzed the medication adherence among patients with gout. (The largest 
sample size among previous studies was the one by Halpern et al. in 2009 with 10,070 
patients.) 







Table 7 displays the details of the patient selection process, which shows that the 
application of the inclusion and exclusion criteria reduced the initial population of 
422,018 gout patients in the database to a final cohort of 91,629, consisting of 11,693 
Febuxostat patients and 79,936 allopurinol patients. 
Table 7 Study Population Selection Process 
 Excluded Remaining 
Unique patients with gout in GEMS  422,018 




Index date in [2009, 2014]   50,863  
 190,919 
Age≥18 and gout Diagnosis prior to Index date   31,446  
 159,473 
At least 6 months of baseline and follow-up   64,376  
   95,097 
Baseline free of index ULT     3,468  
   91,629 
Final Cohort    91,629 
*Group by medications 
   Allopurinol patients 






Table 8 displays the baseline characteristics of the population. Patients are mostly 
male (73.0%), White (66.9%), and over-weight (pre-obese (23.6%) and obese (52.3%)). 





and more than 50% of patients are over 65 years old. Patient population characteristics 
are similar to those of previous studies. 
Having the laboratory data is one of the strengths of this database. However, there 
are many missing values in the laboratory data: 52.0% of patients in the study don’t have 
sUA data and 37.2% of patients don’t have CKD stage information. It is one of the 
limitations of this retrospective database study. The distributions of those with missing 
data for sUA and CKD are not so different from the whole study population. Clinicians 
and previous studies have pointed out that many non-specialist (e.g. GP/Family medicine 
doctors) don’t comply with the guidelines and they don’t order the sUA check although it 
is suggested in the guideline. [36]  Therefore, missing data for sUA might not be random, 
but rather imply the low compliance of physicians to the guidelines. However, it is 
difficult to identify the real reason in this study because of the data limitations. 
Table 8. Study Population Characteristics (entire study population) (N, %) 
 N (%) 
Gender Male 66846 (73.0%) 
Age mean years   63.3 (SD: 13) 
Age Group 18-44 years 9027 (9.9%) 
45-64 35881 (39.2%) 
65+  46721 (51.0%) 
Ethnicity Asian 1739 (1.9%) 
Black 9506 (10.4%) 
Hispanic 1024 (1.1%) 
White 61267 (66.9%) 
Other 2205 (2.4%) 





Region Northeast 23300 (25.4%) 
Midwest 15828 (17.3%) 
South 33565 (36.6%) 
West 18936 (20.7%) 
Insurance Commercial 18457 (20.1%) 
Medicare 38682 (42.2%) 
Other 2697 (2.9%) 
Unknown 31793 (34.7%) 
Index year 2009 17362 (18.9%) 
2010 16710 (18.2%) 
2011 20067 (21.9%) 
2012 19875 (21.7%) 
2013-14 17615 (19.2%) 
BMI Underweight 247 (0.3%) 
Normal 6956 (7.6%) 
pre-Obese 21623 (23.6%) 
Obese 47889 (52.3%) 
Missing 14914 (16.3%) 
CKD Stage Stage1, eGFR >= 90 6152 (6.7%) 
Stage 2, eGFR 60-89 22866 (25.0%) 
Stage 3, eGFR 30-59 23996 (26.2%) 
Stage4+, eGFR < 30 4543 (5.0%) 
Missing 34072 (37.2%) 
Uric Acid sUA < 6 5527 (6.0%) 
sUA 6-6.99 4668 (5.1%) 
sUA 7-7.99 8062 (8.8%) 
sUA 8-8.99 9980 (10.9%) 
sUA ≥ 9 15787 (17.2%) 





Type of physician: 





Tophi or not Tophi 800 (0.9%) 
Renal impairment or not Renal impairment 7208 (7.9%) 
Flares 0 79713 (87.0%) 
1 11755 (12.8%) 
2-3 161 (0.2%) 
Charlson Comorbidity 
Index 
0 74031 (80.8%) 
1 7689 (8.4%) 
2 7009 (7.6%) 
3+ 2900 (3.2%) 
NSAIDs Use or not NSAIDs 26389 (28.8%) 
Steroids Use or not Steroids 17506 (19.1%) 
Colchicine Use or not Colchicine 17911 (19.5%) 
Utilization 0-1 Med 20365 (22.2%) 
2-3 Meds 16283 (17.8%) 
4-6 Meds 23034 (25.1%) 
7-10 Meds 19214 (21.0%) 
11+ Meds 12733 (13.9%) 
 
Table 9 displays the baseline characteristics of the population by type of ULT. 
While the Febuxostat and Allopurinol cohorts are similar in age, sex, ethnic background 
and insurance distributions, there are some differences by region, index year and other 
variables. While some of the differences appear to be minimal—for example in gender—
the p-values for the differences between the two cohorts, driven by the large sample sizes, 





Overall, the Febuxostat treatment group has more patients from the South and less 
from the Northeast, more people who start treatment in the latter Index years, more obese 
patients, higher numbers in the latter stages of CKD, fewer patients with missing uric 
acid test results, and more who received their first prescription from a specialist. 
Additionally, the Febuxostat cohort has a larger percentage of patients with renal 
impairment, taking steroids, colchicine and different types of medications (health 
utilization), painting a picture of a somewhat sicker population compared to the 
Allopurinol group. 
 
Table 9. Population Characteristics (n, % or quantity) by treatment groups 
  TOTAL   
N=91,629 





Gender Male 66846 (73.0%) 58442 (73.1%) 8404 (71.9%) 0.005 
Age mean years   63.3 (SD 13)   63.4 (SD 13)   62.7 (SD 13) <0.0001 
Age Group 18-44 years 9027 (9.9%) 7709 (9.6%) 1318 (11.3%) <0.0001 
45-64 35881 (39.2%) 31321 (39.2%) 4560 (39.0%) 
65+  46721 (51.0%) 40906 (51.2%) 5815 (49.7%) 
Ethnicity Asian 1739 (1.9%) 1471 (1.8%) 268 (2.3%) <0.0001 
Black 9506 (10.4%) 8138 (10.2%) 1368 (11.7%) 
Hispanic 1024 (1.1%) 899 (1.1%) 125 (1.1%) 
White 61267 (66.9%) 53397 (66.8%) 7870 (67.3%) 
Other 2205 (2.4%) 1933 (2.4%) 272 (2.3%) 
Unknown 15888 (17.3%) 14098 (17.6%) 1790 (15.3%) 
Region Northeast 23300 (25.4%) 20876 (26.1%) 2424 (20.7%) <0.0001 
Midwest 15828 (17.3%) 14076 (17.6%) 1752 (15.0%) 





West 18936 (20.7%) 16790 (21.0%) 2146 (18.4%) 
Insurance Commercial 18457 (20.1%) 16143 (20.2%) 2314 (19.8%) <0.0001 
Medicare 38682 (42.2%) 33646 (42.1%) 5036 (43.1%) 
Other 2697 (2.9%) 2446 (3.1%) 251 (2.1%) 
Unknown 31793 (34.7%) 27701 (34.7%) 4092 (35.0%) 
Index year 2009 17362 (18.9%) 16251 (20.3%) 1111 (9.5%) <0.0001 
2010 16710 (18.2%) 14487 (18.1%) 2223 (19.0%) 
2011 20067 (21.9%) 17084 (21.4%) 2983 (25.5%) 
2012 19875 (21.7%) 17068 (21.4%) 2807 (24.0%) 
2013-14 17615 (19.2%) 15046 (18.8%) 2569 (22.0%) 
BMI Underweight 247 (0.3%) 213 (0.3%) 34 (0.3%) <0.0001 
Normal 6956 (7.6%) 6001 (7.5%) 955 (8.2%) 
pre-Obese 21623 (23.6%) 18889 (23.6%) 2734 (23.4%) 
Obese 47889 (52.3%) 41236 (51.6%) 6653 (56.9%) 
Missing 14914 (16.3%) 13597 (17.0%) 1317 (11.3%) 
CKD Stage Stage 1 6152 (6.7%) 5525 (6.9%) 627 (5.4%) <0.0001 
Stage 2 22866 (25.0%) 20266 (25.4%) 2600 (22.2%) 
Stage 3 23996 (26.2%) 20132 (25.2%) 3864 (33.0%) 
Stage 4+ 4543 (5.0%) 3478 (4.4%) 1065 (9.1%) 
Missing 34072 (37.2%) 30535 (38.2%) 3537 (30.2%) 
Uric Acid sUA < 6 5527 (6.0%) 4472 (5.6%) 1055 (9.0%) <0.0001 
sUA 6-6.99 4668 (5.1%) 3893 (4.9%) 775 (6.6%) 
sUA 7-7.99 8062 (8.8%) 6962 (8.7%) 1100 (9.4%) 
sUA 8-8.99 9980 (10.9%) 8618 (10.8%) 1362 (11.6%) 
sUA ≥ 9 15787 (17.2%) 13085 (16.4%) 2702 (23.1%) 
Missing 47605 (52.0%) 42906 (53.7%) 4699 (40.2%) 
Type of 
physician: 
Specialist or not 
Specialist 5387 (5.9%) 4053 (5.1%) 1334 (11.4%) <0.0001 










7208 (7.9%) 5916 (7.4%) 1292 (11.0%) <0.0001 
Flares 0 79713 (87.0%) 69772 (87.3%) 9941 (85.0%) <0.0001 
1 11755 (12.8%) 10037 (12.6%) 1718 (14.7%) 
2-3 161 (0.2%) 127 (0.2%) 34 (0.3%) 
Charlson 0 74031 (80.8%) 64771 (81.0%) 9260 (79.2%) <0.0001 
1 7689 (8.4%) 6753 (8.4%) 936 (8.0%) 
2 7009 (7.6%) 5924 (7.4%) 1085 (9.3%) 
3+ 2900 (3.2%) 2488 (3.1%) 412 (3.5%) 
NSAIDs Use or 
not 
NSAIDs 26389 (28.8%) 22600 (28.3%) 3789 (32.4%) <0.0001 
Steroids Use or 
not 
Steroids 17506 (19.1%) 13990 (17.5%) 3516 (30.1%) <0.0001 
Colchicine Use 
or not 
Colchicine 17911 (19.5%) 14304 (17.9%) 3607 (30.8%) <0.0001 
Utilization 0-1 Med 20365 (22.2%) 19028 (23.8%) 1337 (11.4%) <0.0001 
2-3 Meds 16283 (17.8%) 14508 (18.1%) 1775 (15.2%) 
4-6 Meds 23034 (25.1%) 19865 (24.9%) 3169 (27.1%) 
7-10 Meds 19214 (21.0%) 16254 (20.3%) 2960 (25.3%) 




The basic statistics for the unadjusted adherence are displayed in Table 10. In the whole 
study sample, patients were prescribed an average of 374 days’ supply of drug (median: 210 
days) over a mean follow-up period of 2.2 years. Following established convention in the 





32.0% of patients achieved a personal adherence of at least 80%. The overall mean adherence 
was 46.4%. These numbers are aligned with those which were reported by previous studies. 
(Table 2, Appendix B) 
The same basic statistics are displayed at the bottom of Table 10 for the case when the 
follow-up is limited to the first year after the Index date. During their first year on 
medication, patients were prescribed an average of 181 days’ supply of drug (median: 150 
days) over an average follow-up period of 0.83 years; 51.0% of patients achieved a personal 
adherence of at least 80%. The overall average adherence was 59.5%. 
Table 10. Unadjusted Adherence Analysis Results (Full period, 1 year) 
Supply: mean, median (SD) days 374, 210 (428) 
  Follow-up: mean (SD) years  2.2 (1.4) 
  Individual Adherence ≥ 80% 29,315 (32.0%) 
  Average Adherence 46.4 % 
  
Supply 1-year: mean, median (SD) days 181, 150 (147) 
  Follow-up: mean (SD) years  0.83 (0.3) 
  Individual Adherence ≥ 80% 46,725 (51.0%) 
  Average Adherence 59.5 % 
 
Table 11 shows the basic statistics of unadjusted adherence by medication groups. 
Allopurinol patients were prescribed an average of 396 days’ supply of drug over an average 





days’ supply of drug over an average follow-up period of 1.6 years. 32.2% of Allopurinol 
patients achieved a personal adherence of at least 80%, compared to 30.4% of the Febuxostat 
group. The overall average adherence for the Allopurinol cohort was 47.1%, which was 
substantially higher than the Febuxostat average of 39.0%. Due to the large sample sizes, 
confidence intervals around these averages were very tight. 
Similar to the statistics reported in Table 10, the same basic statistics appear at the bottom 
of Table 11 for the case when the follow-up is limited to the first year after the index date. 
During their first year on medication, Allopurinol patients were prescribed an average of 188 
days’ supply of drug over an average follow-up period of 10 months, while Febuxostat 
patients were prescribed an average of 134 days’ supply of drug over an average follow-up 
period of 9 months. Further, 52.1% of allopurinol patients achieved a personal adherence of 
at least 80%, compared to 43.2% of the Febuxostat group. The overall average adherence for 







Table 11. Unadjusted Adherence Analysis Results by medications (Full period, 1 year) 
 Total    
N=91,629 




Supply: mean, median (SD) days 374, 210 (428) 396, 240 (439) 227, 90 (306) 
  Follow-up: mean (SD) years  2.2 (1.4)  2.3 (1.4) 1.6 (1.3) 
  Individual Adherence ≥ 80% 29,315 (32.0%) 25,758 (32.2%) 3,557 (30.4%) 
  Average Adherence 46.4 % 47.1 % 39.0% 
    
Supply 1-year:  
mean, median (SD) days 
181, 150 (147) 188, 180 (148) 134, 60 (133) 
  Follow-up: mean (SD) years  0.83 (0.3)  0.85 (0.3)  0.73 (0.4) 
  Individual Adherence ≥ 80% 46,725 (51.0%) 41,676 (52.1%) 5,049 (43.2%) 
  Average Adherence 59.5 % 60.6 % 50.5% 
 
It must be pointed out that the quality of the Centricity EMR data left much to be desired. 
The days’ supply was missing in about 44% of all the records.  In those cases, a supply of 30 
days was imputed, as 30 days was reported in 40% of the non-missing prescription lengths, 
by far the most frequent day count. Also, 30 days (1 month) is considered to be a reasonable 
assumption as the usual days of supply based on advice from Dr. Choi, an expert in gout and 






Adjusted Adherence  
A logistic regression was used to model adherence. All 19 covariates produced 
statistically significant parameter estimates, i.e. p-values below 0.05. Using the “Days on 
drug/Total days” as the “k/n” ratio for the dependent variable led SAS to interpret each day 
on drug as an “event” and each of the total days as a “trial,” effectively leading to very large 
sample sizes. This approach, which allowed a natural estimate of adherence for each cohort 
in the unadjusted model, resulted in all covariates being significant with inordinately tight 
confidence intervals.  
 
 
Table 12 displays the estimated odds ratios together with their 95% confidence intervals. The 
odds ratio for treatment was 0.654, meaning that after controlling for the covariates in this 
model, the Febuxostat adherence was significantly lower than that of Allopurinol. Applying 
equation (3.40) of Lachin (2000) [43] to the average adherence for the Allopurinol cohort of 
47.1%, yields 36.8% as the average adherence for Febuxostat, a slightly lower adherence 
than the unadjusted estimate. Among the ethnic groups, only Asians (OR: 1.267) had a 
higher adherence than Caucasians statistically. Black (OR: 0.970) and Hispanic (0.899) 
patients had a lower adherence than Caucasians statistically.  Looking by region, people in 
the Northeast had the highest adherence (OR: 1.155 to Midwest (reference)), while those in 
the South had the lowest (OR: 0.754 to Midwest (reference)), although these regional 
differences may also at least partly reflect differences in the quality of data. People on 
commercial health insurance plans had the highest adherence, compared to those on 
Medicare and others although there are possible confounders including age.  Those who 





users, people with index years 2013-14. Compared to patients with stage 1 (or no) CKD, 
those with stage 4+ CKD (OR: 0.849) had worse adherence, but those with stages 2 (OR: 
1.108) or 3 (OR: 1.059) had higher adherence. Uric acid levels appear to be a good predictor 
of adherence, as higher uric acid levels tend to be associated with better adherence. Patients 
with sUA6-6.99 (OR: 1.044), sUA7-7.99 (OR: 1.067), sUA 8-8.99 (1.145) and those with 
sUA>9 (OR: 1.200) had higher adherence than those with sUA<6. Patients treated by 
specialists (Rheumatologist/Nephrologist) had higher adherence (OR: 1.118) than those 
treated by non-specialists. Patients with tophi had higher adherence (OR: 1.136) than those 
without tophi. Patients using NSAID/Steroid/Colchicine (these medicines can prevent the 
ULT induced flare) had higher adherence than those not using these medications. This 
finding might imply that ULT induced flares are related to low adherence. 
The more medications the patients were on, the higher adherence to gout treatment.  Patients 
with 2-3 medications (OR: 1.261), those with 4-6 medications (OR: 1.348), those with 7-10 
medications (OR: 1.479) and those with 11+ medications (OR:1.528) had higher adherence 
than those with 0-1 medications. While the overall Comorbidity index (Charlson scores) 
were low (less comorbidity), adherence seemed to decrease as the score increased. This 
finding implies that patients with more comorbidities had lower adherence. 
 
 
Table 12. Odds Ratio Estimates of Adjusted Adherence Analysis 
Odds Ratio Estimates and Wald Confidence Intervals 
Effect Estimate 95% Confidence Limits 
Febuxostat (1) vs Allopurinol (0) 0.654 0.653 0.656 





Odds Ratio Estimates and Wald Confidence Intervals 
Effect Estimate 95% Confidence Limits 
Age: 45-64 vs 18-44 1.136 1.134 1.138 
Age: 65+ vs 18-44  1.105 1.103 1.107 
Race: Asian vs White  1.267 1.262 1.271 
Race: Black vs White 0.970 0.968 0.972 
Race: Hispanic vs White  0.899 0.895 0.903 
Race: Other vs White 0.826 0.823 0.829 
Race: Unknown vs White 0.816 0.815 0.817 
Region: Northeast vs Midwest 1.155 1.153 1.157 
Region: South vs Midwest  0.754 0.753 0.755 
Region: West vs Midwest  0.808 0.807 0.810 
Insurance: Medicare vs Commercial  0.832 0.831 0.834 
Insurance: Other vs Commercial  0.519 0.517 0.520 
Insurance: Unknown vs Commercial  0.889 0.888 0.890 
Index Year: 2010 vs 2009 0.815 0.813 0.816 
Index Year: 2011 vs 2009 0.874 0.872 0.875 
Index Year: 2012 vs 2009 0.928 0.926 0.930 
Index Year: 2013-14 vs 2009 1.157 1.154 1.160 
BMI: Missing vs Normal 0.956 0.954 0.958 
BMI: Obese vs Normal 1.112 1.110 1.114 
BMI: Underweight vs Normal 0.999 0.989 1.009 
BMI: pre-Obese vs Normal 1.050 1.048 1.052 





Odds Ratio Estimates and Wald Confidence Intervals 
Effect Estimate 95% Confidence Limits 
CKD stage: Stage 3 vs Stage 1 1.059 1.056 1.061 
CKD stage: Stage2 vs Stage 1 1.108 1.105 1.110 
CKD stage: Missing vs Stage 1 0.931 0.929 0.933 
SUA: sUA 6-6.99 vs sUA < 6 1.044 1.041 1.047 
SUA: sUA 7-7.99 vs sUA < 6 1.067 1.064 1.070 
SUA: sUA 8-8.99 vs sUA < 6 1.145 1.142 1.148 
SUA: sUA ≥ 9 vs sUA < 6 1.200 1.198 1.203 
SUA: Missing vs sUA < 6 0.821 0.819 0.823 
Specialist (1) vs Non-specialist (0) 1.088 1.086 1.091 
Tophi (1) vs Non-Tophi (0) 1.136 1.130 1.143 
Renal impairment (1) vs Non-Renal impairment (0) 1.056 1.053 1.060 
Number of Flares 1 vs 0 1.005 1.003 1.006 
Number of Flares 2-3 vs 0 0.959 0.948 0.971 
Charlson Index 1 vs 0 0.878 0.877 0.880 
Charlson Index 2 vs 0 0.830 0.828 0.833 
Charlson Index 3+ vs 0 0.723 0.720 0.725 
NSAID use (1) vs No NSAID use (0) 1.053 1.052 1.054 
Steroid Use (1) vs No Steroid Use (0) 1.056 1.054 1.057 
Colchicine Use (1) vs No Colchicine Use (0) 1.092 1.090 1.093 
Utilization: 2-3 Meds vs 0-1 Med 1.261 1.259 1.263 
Utilization: 4-6 Meds vs 0-1 Med 1.348 1.346 1.350 





Odds Ratio Estimates and Wald Confidence Intervals 
Effect Estimate 95% Confidence Limits 
Utilization: 11+ Meds vs 0-1 Med 1.528 1.525 1.530 
 
 
One-year Adherence  
Truncating the follow-up at one year yielded almost identical results to the full period. 
Again, all the covariates produced significant parameter estimates, with the magnitudes of 
the odds ratios being very similar. The odds ratio for treatment was 0.618, slightly lower than 
the odds ratio which used the entire follow-up.  
Another, more traditional, approach to modeling adherence is to use the indicator of 
personal adherence of at least 80% as the response in a logistic model. As Table 13 displays, 
the results fell in line with those discussed already. In this model, most covariates, but not all, 
yielded significant parameter estimates—the exceptions being flare count, renal impairment, 
NSAID use, and glucocorticoids.   
 
Table 13. Odds Ratios of Adjusted Adherence Analysis at 1 year 
Odds Ratio Estimates and Wald Confidence Intervals 
Effect Estimate 95% Confidence Limits 
Febuxostat (1) vs Allopurinol (0) 0.669 0.642 0.697 
Gender:  Male (1) vs Female (0) 1.072 1.038 1.107 
Age: 45-64 vs 18-44 1.16 1.105 1.218 





Odds Ratio Estimates and Wald Confidence Intervals 
Effect Estimate 95% Confidence Limits 
Race: Asian vs White  1.057 0.957 1.168 
Race: Black vs White 0.855 0.816 0.895 
Race: Hispanic vs White  0.782 0.687 0.889 
Race: Other vs White 0.695 0.636 0.759 
Race: Unknown vs White 0.756 0.729 0.785 
Region: Northeast vs Midwest 1.052 1.009 1.098 
Region: South vs Midwest  0.735 0.706 0.765 
Region: West vs Midwest  0.804 0.769 0.841 
Insurance: Medicare vs Commercial  0.848 0.813 0.884 
Insurance: Other vs Commercial  0.516 0.474 0.563 
Insurance: Unknown vs Commercial  0.892 0.858 0.927 
Index Year: 2010 vs 2009 0.594 0.565 0.624 
Index Year: 2011 vs 2009 0.544 0.517 0.572 
Index Year: 2012 vs 2009 0.453 0.429 0.479 
Index Year: 2013-14 vs 2009 0.412 0.388 0.438 
BMI: Missing vs Normal 0.938 0.883 0.996 
BMI: Obese vs Normal 1.125 1.067 1.186 
BMI: Underweight vs Normal 1.019 0.785 1.324 





Odds Ratio Estimates and Wald Confidence Intervals 
Effect Estimate 95% Confidence Limits 
CKD stage: Stage 4+ vs Stage 1 1.055 0.993 1.122 
CKD stage: Stage 3 vs Stage 1 1.073 1.012 1.138 
CKD stage: Stage2 vs Stage 1 0.897 0.825 0.975 
CKD stage: Missing vs Stage 1 0.871 0.821 0.924 
SUA: sUA 6-6.99 vs sUA < 6 1.079 0.996 1.169 
SUA: sUA 7-7.99 vs sUA < 6 1.117 1.04 1.199 
SUA: sUA 8-8.99 vs sUA < 6 1.183 1.105 1.267 
SUA: sUA ≥ 9 vs sUA < 6 0.877 0.826 0.931 
SUA: Missing vs sUA < 6 1.243 1.165 1.326 
Specialist (1) vs Non-specialist (0) 1.118 1.055 1.185 
Tophi (1) vs Non-Tophi (0) 1.17 1.012 1.352 
Charlson Index 1 vs 0 0.861 0.82 0.905 
Charlson Index 2 vs 0 0.875 0.83 0.921 
Charlson Index 3+ vs 0 0.705 0.651 0.763 
NSAID use (1) vs No NSAID use (0) 1.078 1.04 1.117 
Utilization: 2-3 Meds vs 0-1 Med 1.568 1.489 1.652 
Utilization: 4-6 Meds vs 0-1 Med 1.241 1.187 1.297 
Utilization: 7-10 Meds vs 0-1 Med 1.391 1.333 1.45 






Unadjusted Persistence  
The basic statistics for the unadjusted persistence are displayed in Table 14. For the 
whole study sample, 34.8% of patients had a gap between prescriptions that qualified as non-
persistence.  The patients had a rate of 50.9 incidents of non-persistence per 100 person-
years, with a 95% confidence interval of [50.3, 51.4]. The patients with an “active flag,” 
which means patients on the medication as of the last data collection point, was 77.5%.  
 
Table 14. Unadjusted Persistence Analysis Results 
Person-years 62,767 
Non-persistent patients (%) 31,929 (34.8) 
Incidence of non-persistence (per 100 person-years) 50.9 [50.3, 51.4] 
Active users (%) 70,992 (77.5) 
Median Time to non-persistence  1.468 years 
 
 
The basic statistics for the unadjusted persistence by medication groups are displayed in 
Table 15. As noted above, Allopurinol patients had a longer follow-up period, which means 
they stayed on the drug longer. So even though 36% of Allopurinol patients had a gap 
between prescriptions that qualified as non-persistence, compared to only 27% of Febuxostat 
patients, the length of time on Allopurinol tended to be longer, and thus persistence was 
higher overall among Allopurinol patients. This is reflected in the estimates of the incidence 
of non-persistence. Allopurinol had a rate of 49.7 incidents of non-persistence per 100 
person-years, with a 95% confidence interval of [49.2, 50.3], while Febuxostat had a rate of 





66.2]. The “active flag” was turned on for 81% of the Allopurinol cohort—patients on the 
medication as of the last data collection point—compared to 55% of the Febuxostat group. 
However, the overall difference in persistence was minimal, with the hazard ratio (HR) for 
Febuxostat at 1.05—although the p-value was 0.0074 due to the large sample size.  
 
 
Table 15. Unadjusted persistence analysis results by medications 




Person-years 62,767 57,809 4,958 
Non-persistent patients (%) 31,929 (34.8) 28,758 (36.0) 3,171 (27.1) 
Incidence of non-persistence 
(per 100 person-years) 
50.9 [50.3, 51.4] 49.7 [49.2, 50.3] 64.0 [61.7, 66.2] 
Active users (%) 70,992 (77.5) 64,567 (80.8) 6,425 (54.9) 
Median Time to non-
persistence 
 1.468 years  1.475 years  1.383 years 
Hazard ratio   1.05 [1.01, 1.09] 
 
The median time to non-persistence, estimated from the data used to create the Kaplan-







Figure 14. Unadjusted Persistence-- Kaplan-Meier estimate of cumulative Pr (persistence) 
 
 
Adjusted Persistence  
A proportional hazards model or Cox regression was used to model persistence.  
A stepwise selection algorithm was used, and covariates with p-values below 0.05 
were retained in the model. Table 16 displays covariate p-values for the persistence Cox 









excluded due to p values above 0.05, including Gender, Specialist provider, Tophi, 
Charlson Index, NSAID, Steroids and Colchicine. There are 2 other covariates with 
p>0.05, Renal and Flares, but these eventually were included in the final model through 
the stepwise process. Table 17 displays the same 7 covariates assessed individually at the 
end of the forward elimination process, where the running Cox model contains the 12 
significant covariates. This result also shows p>0.05, although the sizes of the p-values 
have changed. 
 
Table 16. Stepwise selection process (1): Covariate p-values for the persistence Cox model (All 19 
covariates) 
Parameter Wald Chi-Square Pr > ChiSq 
Febuxostat  14.7107 0.0001 
Gender 0.2891 0.5908 
Age 62.8104 <.0001 
Race 187.0682 <.0001 
Region 104.9041 <.0001 
Insurance 37.8042 <.0001 
Index Year 692.6207 <.0001 
BMI 27.1499 <.0001 
CKD stage 12.3848 0.0147 
SUA 77.5536 <.0001 
Specialist 0.0019 0.9651 
Tophi 0.9902 0.3197 
Renal impairment 2.1410 0.1434 
Acute gout arthritis 5.8154 0.0546 
CCI 6.7174 0.0815 





Steroid use 3.1235 0.0772 





Table 17. Stepwise selection process (2): Analysis of Effects Eligible for Entry 
Effect Score 
Chi-Square 
Pr > ChiSq 
Gender 0.3060 0.5801 
Specialist 0.0896 0.7646 
Tophi 1.0234 0.3117 
CCI 6.4942 0.0899 
NSAID use 1.2985 0.2545 
Steroid use 3.1825 0.0744 
Colchicine use 0.1338 0.7145 
 
 
Through the process described above, the stepwise model retained 12 of the 19 
available covariates. Table 18 lists the estimated HRs together with their 95% confidence 
intervals. It should be noted that the overall test for the CKD stage variable yielded a p-
value below 0.05, even if none of the categories that make up the variable had a 
significant HR. The hazard ratio for treatment is 1.07, meaning that after controlling for 
the covariates in this model, the Febuxostat persistence is significantly lower than that of 





shorter for the Febuxostat cohort. Applying the HR to the allopurinol raw incidence of 
non-persistence yields 53.4 non-persistent patients per 100 person-years for Febuxostat, a 
lower incidence than the unadjusted estimate. 
 
Persistence on ULTs apparently improves with age, as the two older age groups 
have HRs that are less than one and are decreasing. Among the ethnic groups, Hispanics 
and Blacks have worse persistence than Caucasians, whose persistence was about the 
same as that of Asians. The Northeast was the region with the highest persistence, while 
the South had the lowest. Similarly, to the adherence finding, people on commercial 
health insurance plans had the highest persistence, compared to those on Medicare and 
others. Those who started on an ULT in 2009 (reference group) and 2011 had equivalent 
levels of persistence, better than those who started in 2010, but not as high as the most 
recent users, people with index years 2012-14. There is some evidence that patients with 
higher levels of uric acid tend to have higher persistence. Looking at the health utilization 
measure, better persistence to ULTs is found among patients taking more medications. 
 
 
Table 18. Hazard Ratios of Adjusted Persistence Analysis– Cox regression results 
Analysis of Maximum Likelihood Estimates 
Parameter   p-value Hazard 
Ratio 
95% Hazard Ratio Conf 
Limits 
Medication     Febuxostat (1) vs 
Allopurinol (0) 





Analysis of Maximum Likelihood Estimates 
Parameter   p-value Hazard 
Ratio 
95% Hazard Ratio Conf 
Limits 
Age 45-64 vs 18-44 <.0001 0.893 0.859 0.929 
65+ vs 18-44 <.0001 0.841 0.806 0.879 
Race Asian vs White 0.4774 1.029 0.951 1.114 
Black vs White <.0001 1.107 1.067 1.149 
Hispanic vs White 0.0268 1.120 1.013 1.237 
Other vs White <.0001 0.710 0.652 0.772 
Unknown vs White <.0001 0.868 0.841 0.896 
Region North East vs Midwest <.0001 0.910 0.879 0.942 
South vs Midwest 0.0013 1.055 1.021 1.090 
West vs Midwest 0.1267 1.029 0.992 1.066 
Insurance Medicare vs Commercial <.0001 1.108 1.071 1.146 
Other vs Commercial 0.0753 1.069 0.993 1.150 
Unknown vs 
Commercial 
<.0001 1.088 1.054 1.122 
Index year 2010 vs 2009 <.0001 1.148 1.108 1.189 
2011 vs 2009 0.9980 1.000 0.962 1.039 
2012 vs 2009 <.0001 0.817 0.782 0.854 
2013-14 vs 2009 <.0001 0.496 0.470 0.525 
BMI Missing vs Normal <.0001 1.108 1.053 1.166 
Obese vs Normal 0.2030 1.030 0.984 1.078 
Underweight vs Normal 0.0829 0.794 0.611 1.030 





Analysis of Maximum Likelihood Estimates 
Parameter   p-value Hazard 
Ratio 
95% Hazard Ratio Conf 
Limits 
CKD stage Stage 4+ vs Stage 1 0.0992 1.060 0.989 1.135 
Stage 3 vs Stage 1 0.1458 1.038 0.987 1.091 
Stage 2 vs Stage 1 0.9959 1.000 0.953 1.049 
Missing vs Stage 1 0.5513 0.985 0.939 1.034 
sUA sUA 6-6.99 vs sUA < 6 0.0996 0.946 0.885 1.011 
sUA 7-7.99 vs sUA < 6 0.0094 0.925 0.872 0.981 
sUA 8-8.99 vs sUA < 6 0.0052 0.923 0.872 0.976 
sUA ≥ 9 vs sUA < 6 0.0969 0.956 0.908 1.008 
Missing vs sUA < 6 0.0210 1.059 1.009 1.111 
Diagnosis of renal 
impairment 
Renal impairment (1) vs 
Non-Renal impairment 
(0) 
<.0001 1.094 1.049 1.142 
Number of 
diagnoses of acute 
gout arthritis 
1 vs 0 0.0056 0.950 0.916 0.985 
2-3 vs 0 0.8765 1.021 0.782 1.335 
Heath care 
utilization  
2-3 Meds vs 0-1 Med <.0001 0.903 0.871 0.937 
4-6 Meds vs 0-1 Med <.0001 0.876 0.846 0.907 
7-10 Meds vs 0-1 Med <.0001 0.850 0.819 0.882 








Subgroup Analysis  
In addition to analyzing the entire study population, I conducted two sub-group 
analyses. Two subgroups of the full study cohort were compared in terms of their 
unadjusted adherence and persistence, as well as their adjusted adherence: (i) patients 
who had tophi or at least one flare at baseline, and (ii) patients who were prescribed 
NSAIDs, steroids or colchicine at baseline. These factors are included as covariates in the 
adjusted analysis, because it is considered meaningful to investigate the patient behavior 
of the population who might have higher medical needs and those who might have more 
treatment induced flares. The severity of disease status and importance of prophylaxis 
might have major impacts on medication adherence based on the results from previous 





Baseline flares or tophi 
About 13.4% of all study patients had either tophi or at least one flare during the 
6-month baseline. The basic statistics comparing the unadjusted adherence between drug 
treatments were displayed in Table 18, while the unadjusted persistence was shown in 
Table 19. Within this subgroup, allopurinol patients obtained a larger supply of drug and 
were more adherent than Febuxostat patients. The two treatment groups had very similar 
measurements of uric acid at baseline, both with a mean of 8.7.  
The same basic adherence statistics appear at the bottom of Table 19 for the case 
when the follow-up is limited to the first year after the index date. The overall rates of 
adherence were higher than over the full follow-up period, while the differences between 
the two treatment groups were comparable. Modeling adherence with the covariates 
included as in the full population—but omitting the covariates which defined the 
subgroup—yielded an odds ratio for treatment of 0.676, with p<0.0001, meaning that the 
adjusted Febuxostat adherence was statistically significantly lower than that of 
Allopurinol. Applying the formula to convert the odds ratio to a relative risk yielded 
43.8% as the average adherence for Febuxostat, a slightly lower adherence than the 
unadjusted estimate in Table 19. A logistic regression using the indicator of personal 
adherence of at least 80% as the dependent variable yielded very similar results 
(OR=0.715). 
As in the full cohort, a larger percentage (34%) of Allopurinol patients in the 
subgroup had a gap between prescriptions that qualified as non-persistence, compared to 
Febuxostat patients (27%), but time on Allopurinol tended to be longer, and thus 





higher estimate of incidence of non-persistence among Febuxostat patients—the raw 
hazard ratio of 1.17 achieved significance with a p-value of 0.001. 
 
Table 19. Unadjusted Adherence among patients with 1+ Flares or Tophi (N=12,533) 
 Allopurinol     N=10,647 Febuxostat   N=1,886 
Supply: mean, median (SD) days 413, 276 (417) 242, 114 (313) 
Follow-up: mean (SD) years 2.1 (1.4) 1.5 (1.3) 
Individual Adherence ≥ 80% 4,143 (38.9%) 670 (35.5%) 
Adherence 53.6% 44.6 % 
   
1-year only   
  Individual Adherence ≥ 80% 5,951 (55.9%) 896 (47.5%) 








Table 20. Unadjusted Persistence among patients with 1+ Flares or Tophi (N=12,533)  
 Allopurinol     
N=10,647 
Febuxostat   
N=1,886 
Person-years 8,580 868 
Non-persistent patients (%) 3,642 (34.2) 511 (27.1) 
Incidence of non-persistence (per 
100 person-years) 
42.4 [41.1, 43.8] 58.9 [53.9, 64.2] 
Active users (%) 8,269 (77.7) 966 (51.2) 
Median Time to non-persistence  1.963 years  1.458 years 
Hazard ratio  1.17 [1.06, 1.28] 
 
 
Baseline NSAIDs, steroids or colchicine 
About 48.9% of all study patients were prescribed either NSAIDs, steroids or 
colchicine during the 6-month baseline. The basic statistics comparing the unadjusted 
adherence were displayed in Table 21, while the unadjusted persistence was shown in 
Table 22. Again, Allopurinol patients obtained a larger supply of drug and were more 
adherent than Febuxostat patients. The two treatment groups had very similar 
measurements of uric acid at baseline, with means of 8.5 in the Allopurinol group and 8.4 
in the Febuxostat group.  
The same basic adherence statistics appear at the bottom of Table 21 for the case 
when the follow-up is limited to the first year after the index date. The overall rates of 
adherence were higher, and the difference between the two treatment groups was higher 





as in the full population—but omitting the covariates which defined the subgroup—
yielded an odds ratio for treatment of 0.672, with p<0.0001, meaning that the adjusted 
Febuxostat adherence was significantly lower than that for the Allopurinol group A 
logistic regression using the indicator of personal adherence of at least 80% as the 
dependent variable yielded very similar results (OR=0.680). 
From the results in Table 22, more Allopurinol patients were non-persistent over 
the follow-up than Febuxostat patients (37% vs. 29%), but the incidence of non-
persistence was higher among Febuxostat patients—the raw hazard ratio of 1.15 achieved 
significance with a p-value below 0.001. 
 
Table 21. Unadjusted Adherence among patients with NSAIDs, Steroids or Colchicine (N=44,849) 
 
Allopurinol     
N=37,468 
Febuxostat   N=7,381 
Supply: mean, median (SD) days 434, 300 (444) 249, 115 (323) 
Follow-up: mean (SD) years 2.3 (1.4) 1.6 (1.3) 
Individual Adherence ≥ 80% 13,665 (36.5%) 2,438 (33.0%) 
Adherence 51.8% 42.4 % 
1-year only   
  Individual Adherence ≥ 80% 21,108 (56.3%) 3,409 (46.2%) 






Table 22. Unadjusted Persistence among patients with NSAIDs, Steroids or Colchicine (N=44,849)  
 Allopurinol     
N=37,468 
Febuxostat   
N=7,381 
Person-years 30,515 3,384 
Non-persistent patients (%) 13,784 (36.8) 2,153 (29.2) 
Incidence of non-persistence (per 
100 person-years) 
45.2 [44.4, 45.9] 63.6 [61.0, 66.4] 
Active users (%) 29,343 (78.3) 3,812 (51.7) 
Median Time to non-persistence  1.766 years  1.225 years 







Chapter 5 Discussion/Conclusions  
Discussion of findings from the Adherence analysis 
This study provided a more comprehensive view about the adherence of patients with gout 
because the total sample size of this study is 91,629 patients, which is much larger than those of 
previous studies which analyzed medication adherence among patients with gout. In addition, the 
distributions of demographics in the database used for this study are generally similar to that of 
the overall U.S. population whereas some previous studies focused on specific subpopulations. 
Baseline characteristics of study population are similar with the previous studies. At the 
baseline, those prescribed Febuxostat were more obese patients, had higher numbers in the latter 
stages of CKD, had fewer patients with missing uric acid test results, and more who received 
their first prescription from a specialist. Considering that the careful dose adjustment is required 
to prescribe Allopurinol for higher CKD patients (Febuxostat is considered to have relatively less 
burden for CKD patients because of the mechanism), the differences in CKD between the 2 
groups are reasonable. Also, the findings are consistent with the previous findings that specialists 
seek the newly available treatment with the branded medicine. Also “unlearning” might be 
related in terms of the practice changes which may be required of physicians (especially non-
specialists).  Gupta et al pointed out that physicians face various struggles in order to 
successfully change practice when a change is introduced (e.g. guideline changes) in their 
qualitative study of the practices of the general physicians. They mentioned that the guideline 
change and new information makes for uncertainty and discomfort which may inhibit behavior 





In the unadjusted adherence analysis with the total study population, 32.0% of patients 
achieved a personal adherence of at least 80% and the overall average adherence was 46.4%. 
These numbers are considered to be aligned with those which were reported by previous studies. 
In three previous studies, 36.8 % (Briesacher et al. 2008), 36% (Solomon et al. 2008) and 44% 
(Halpern et al. 2009) of patients achieved a personal adherence of at least 80%.[30] [32] [33] As 
confirmed in Chapter 2, the adherence among gout patients has been significantly low, compared 
with other chronic diseases. For example, in the study by Briesacher et al. (2008), 72.3 % of 
hypertension patients achieved a personal adherence of at least 80% whereas 36.8% of gout 
patients did. [30] This finding suggests that there is a large room to improve the adherence of 
patients with gout.  
In the unadjusted analysis by medication groups, 32.2 % of patients with Allopurinol and 
30.4 % of those with Febuxostat achieved a personal adherence of at least 80%. According to 
Schulman K, the monthly cost for Allopurinol was 5 USD whereas the cost for Febuxostat was 
155 USD. [45] Considering the drug price difference between Allopurinol and Febuxostat, this 
difference in personal adherence could well be due to the price difference as suggested by market 
research which has found generally higher patient co-pays for Febuxostat. This may help explain 
the lower adherence among patients on Febuxostat. Because of the data limitations of this 
database, it is difficult to reach conclusions, but the difference in adherence may also be related 
to SES factors and insurance status.  
In the adjusted analysis, one of biggest factors associated with adherence was the medication, 
with an odds ratio which was 0.654. The Febuxostat adherence was significantly lower than that 
of Allopurinol after controlling for the covariates in this model. The reasons why medication had 





substantial difference in cost between Allopurinol and Febuxostat.), and 2) Possibly better 
effectiveness (Considering the mechanism of ULT induced flare, the more effective treatment 
may have higher risk of further attack which might have made patients stop taking medications. 
The number of flares at baseline were controlled, but the flares that occurred in follow-up were 
not controlled.) More details about possible interventions to improve adherence will be discussed 
in the following section. In addition, a concern regarding cardiovascular risk related to 
Febuxostat was mentioned by the FDA when it was launched in the US market. This also might 
have impacted patients’ behaviors.   
Other than medication, several factors were identified as factors associated with gout 
medication adherence. Figure 15 is the Conceptual Framework for Gout Medication Adherence 
which was developed based on the review of previous studies. The elements identified as 
important in this study are highlighted in the Figure below.   
• Some elements (weather, food culture) were not included in the database, but are 
considered to be related to some of the other factors in this analysis (region, race). 
• Some elements in the conceptual framework (type of healthcare system, reminder 
system or not, individual belief/knowledge, etc.) could not be studied because they 
are not available in the database.  
• Some elements in the conceptual framework (acute treatments, number of gout flares, 
etc.) were studied, but a clear relationship with adherence to gout medications could 
not be determined. (The results of the statistical analysis were significant because the 
sample size was large, however either the results were not strong compared with other 














Discussion of findings from the Persistence analysis 
In the unadjusted analysis, 31929 patients (34.8% of all patients) had a gap between 
prescriptions which is considered as non-persistence.  The patients had a rate of 50.9 incidents of 
non-persistence per 100 person-years, with a 95% confidence interval of [50.3, 51.4]. The 
patients with an “active flag,” which means patients were on the medication as of the last data 
collection point, was 77.5%. Median time to non-persistence in the unadjusted analysis was 
1.468 years. Compared with the previous study by Solomon et al, [32] median time was a little 
bit longer, but the overall trends were similar. 
In the adjusted analysis, as in the case with the adherence analysis above, the type of 
medication had a significant impact on persistence. Patients on Febuxostat had a significantly 
lower persistence than those on allopurinol. Other factors also had similar trends with the 
adherence analysis described above. Persistence apparently improves with age. Among the 
ethnic groups, Hispanics and Blacks have worse persistence than Caucasians, whose persistence 
was about the same as that of Asians. The Northeast was the region with the highest persistence, 
while the South had the lowest. Patients with commercial health insurance plans had the highest 
persistence, compared to those with Medicare and other types of insurance. 
 
Discussion of findings from subgroup analysis 
In addition to analyzing the entire study population, two sub-group analyses were conducted 
for the following: (i) patients who had tophi or at least one flare at baseline, and (ii) patients who 
were prescribed NSAIDs, steroids or colchicine at baseline. These factors were included as 





patient behavior of the populations who might have higher medical needs and those who might 
have more treatment induced flares. Although there was a hypothesis that these factors might 
have impacts on patient behaviors, significant differences from the results for the entire study 
population were not found.  
 
Conclusions and Implications for Interventions to improve Adherence and 
Persistence  
Conclusions 
The difference between the types of medication (Febuxostat or Allopurinol) used for ULT 
was one of the factors associated with patient adherence to chronic gout medication from the 
standpoint of statistical (although not necessarily clinical) significance.  As discussed above, the 
following reasons may be considered in explaining this trend. 
1) The cost difference between Febuxostat and Allopurinol 
As mentioned above, there is a significant price difference between Febuxostat 
and Allopurinol, as suggested by market research which has found generally higher 
patient co-pays for Febuxostat. This may explain the lower adherence among patients on 
Febuxostat. 
2) Better effectiveness of Febuxostat on lowering sUA  
Considering the mechanism of ULT induced flare, better effectiveness may lead 
to the higher risk of further attack. [35] (Numbers of flares at baseline were controlled in 





might make patients stop taking medications. [46] As Odera et al. have pointed out, 
prophylaxis to prevent further attack is generally not enough and physicians do not 
follow the guideline which recommends the prophylaxis. [36] 
However, because switching between medications cannot be analyzed in this study, 
further research to consider patients’ behavior after switching medicines is needed to reach better 
conclusions regarding the impact of medications on adherence. 
Other than type of medication, the analysis identified the following factors which are 
associated with gout medication adherence. The findings from this study are consistent with 
those which were reported in the previous studies. The factors in () are associated with higher 
adherence. 
• Gender (Female > Male) 
• Race (Asian > Caucasian; > Black; > Hispanic) 
• Region (Northeast > Midwest; > West; > South) 
• Insurance (Commercial > Medicare) 
• BMI (Obese > Pre-obese; > Normal; > Underweight) 
• CKD stage (Stage 2 > Stage 3; > Stage 1; > Stage 4) 
• Specialist vs. Non-specialist provider classifications (Specialist > Non-specialist) 
• Diagnosis of gout tophi (With tophi > Without tophi) 
• Diagnosis of renal impairment  
• Serum uric acid measurements (Higher sUA > Lower sUA) 
• Number of diagnoses of acute gout arthritis (gout flares, separated from each other by 





• Comorbidities (Quantified with the Charlson Comorbidity Index (CCI)) (3+ > 2; > 1; 
> 0) 
• Use of NSAIDs (With NSAID > Without NSAID) 
• Use of colchicines (With Colchicines > Without Colchicines) 
• Use of glucocorticoids (With steroids > Without steroids) 
• Heath care utilization (number of different types of medications used during baseline) 
(11+ > 7-10; > 4-6; > 2-3; > 0-1) 
 
Possible interventions to improve Adherence and Persistence 
Based on the analysis results and the conceptual framework derived from the results of 
previous studies, several interventions can be considered to improve the adherence and 
persistence to gout medications. 
Cost burden mitigation 
In this study, the analysis results showed that the type of insurance is associated with both 
adherence and persistence.  In both analyses, patients with commercial insurance had better 
adherence and persistence compared to those with Medicare, other types of insurance and 
unknown insurance status. Because this database does not have other items related to financial 
matters, it is difficult to draw conclusions, but the implication is that the cost burden is one of the 
factors which have a negative impact on adherence.  
For those who cannot afford gout medication due to financial reasons, there are several 





these programs. Most patients who can access a minimum level of health services, but not higher 
quality services, cannot utilize these support programs. [47] 
In addressing the price difference between Febuxostat and Allopurinol, there are some 
programs to support the cost of Febuxostat from Takeda, a pharmaceutical company who is 
manufacturing Febuxostat. But all programs sponsored by them are only available for the first 90 
days. Considering that the drop in adherence happened at 90 days, their programs might not be 
enough to keep patients on medications.  As a possible intervention to mitigate the cost burden of 
gout medications (especially brand-generic price differences), the development of expanded 
(beyond 90 days) coupon programs should be considered with the support from a brand medicine 
manufacturer. In the mid-/long- range, after the Febuxostat patent expiration which will occur in 
a few years, the price differences between Febuxostat and Allopurinol will be decreased.  
In addition, some may argue that insurance companies tend to underestimate the threat of 
gout and consider gout as just a temporary inflammatory attack creating pain which can be 
simply controlled by NSAIDs. However, as discussed in Chapter 2, the negative impact of gout 
on other complications (e.g. CKD, DM, CV risk) in the long-term suggest that gout should be 
treated as a chronic disease with adequate treatments in the long-term, not just as a single 
incident. Encouraging the insurance companies to reconsider their recommended treatment 
plan/coverage also can be a possible way to mitigate the financial burden of gout management.   
 
Patient education / Reminder systems 
To improve the adherence to gout medications, one of the most important things is to make 





is known as a disease which patients don’t understand well. Spencer et al. pointed out the lack of 
knowledge and understanding of the causes and consequences of gout and that it can be treated 
effectively by lifestyle change and use of urate lowering therapy (ULT). They also reported that 
many patients viewed gout as self-inflicted or part of ageing and only focused on managing acute 
attacks, rather than treating the underlying cause. [48] Coburn et al. reported that the majority of 
gout patients didn’t understand the treatment goals. Of the 62 percent of patients who answered 
their questionnaire, only 14 percent knew a target sUA and nearly 80 percent expressed a general 
lack of knowledge about their treatment goals [49].  
In this study, because of the data limitations of the retrospective analysis of secondary data, 
the factors which are directly related to patient education and awareness are not included in the 
analysis. However, several factors which might be indirectly related (Age, Gender, Race, 
Region, seeing specialists/non-specialists and Utilization) imply that the patients’ 
backgrounds/knowledge of disease might be related to the adherence.   
In order to find solutions to patients’ disease awareness issues, Rees et al. conducted a study 
with a nurse-delivered intervention that included education, individualized lifestyle advice and 
appropriate ULT and confirmed that the intervention could successfully achieve the 
recommended treatment target in more than 90% of patients. [50] Also, several nonprofit 
organizations provide patient education tools targeting patients directly (mostly available through 
the websites) and indirectly via healthcare professionals. Through the collaboration with these 
organizations, a targeted patient education campaign focusing on vulnerable populations (based 






Related to patient education, a reminder system is also important to consider as a possible 
solution to how to improve patient behavior regarding adherence, as identified through the 
analysis based on the conceptual framework discussed above. With the current technology, there 
are several methods to remind patients to follow the chronic disease management. Especially, the 
reminder systems using apps available on smartphones are widely available. Some apps have 
several functions, not only simpler reminders but also disease education and life style advice. 
However, compared with other therapeutic areas like Disease Management, there are very few 
apps focusing on gout management. Nguyen et al. concluded in their study of 57 identified apps, 
that only one app exists that includes all recommendations to facilitate patient self-management 
of gout. [51] Their manuscript was published 2 years ago in 2016. But the situation since then 
has not changed very much. As one of the interventions to improve gout adherence, the 
development of new apps might be worth considering. 
 
Physician education  
To improve the patients’ knowledge about gout management, physician education is 
considered to be critical.  
As discussed in Chapter 2, Odera et al. pointed out that there is room to improve the 
physicians’ treatment compliance with ACR guidelines among both primary care physicians 
(PCPs) and rheumatologists. Although both specialists and PCPs have room to improve, they 
reported that PCPs are less compliant with the treatment guidelines than rheumatologists. [36] As 
mentioned previously regarding the lack of knowledge on the patients’ side, Doherty et al. 





physicians. They also discussed that physicians often focus on managing acute attacks rather 
than viewing gout as a chronic disease because of the lack of adequate physician education. [52] 
Also as discussed, “unlearning” may be necessary for the practice change of physicians 
(especially non-specialists), and they may face various struggles in order to successfully change 
practice when a change is introduced (e.g., guideline change, new innovation).  [44] 
This study found that there is a positive association with adherence if the physician is a 
specialist (rheumatologist/ nephrologist). This finding may suggest that physicians’ knowledge 
about gout management might be related to adherence. Based on this supposition, physician 
education, especially focusing on GP/Family medicine physicians, might be an effective 
intervention to improve patients’ adherence to gout treatments. 
 
Strengths and Limitations of this Study 
As mentioned above, this study is the first comprehensive study which examined the 
medication adherence to Febuxostat, a new medication option launched in 2009 in the large U.S. 
population.  As a benefit of the large EMR database, the sample size of this study is much larger 
than those of previous investigations and the data cover a broader range of regions and 
populations compared with the previous studies. The findings from this comprehensive study 
strengthen the findings from previous studies, contribute to clarifying the causes of low 
adherence to chronic gout medications (which may create repeated flares leading to lower 
HRQoL and higher medical costs), and have implications for solutions to improve the current 





At the same time that there are benefits of the large EMR database, there are also several 
limitations. Because the database is completely de-identified following the HIPPA regulation, 
some information is not available in the database and individual patients cannot be linked with 
other databases to obtain additional information. Also, there are missing values, especially in the 
laboratory and prescription data. Although significant differences in terms of missing data 
among groups was not found in this study, concerns remain. This is one of the big challenges in 
using existing databases for analysis. 
As another limitation of the database used in this study, adherence cannot be measured with 
the tools confirming the actual intake of medication (e.g. the usage of special bottles examined in 
the data collection). Also, the EMR database contains prescription data, but not the filling data.  
It is reported that about a third of patients fail to fill their first-time prescriptions [53]. Also, it is 
not possible to detect the relationship between the prescription and actual filling of the 
prescription in the analysis with this EMR database.  Therefore, it is important to admit the 
possibility that there exist unadjusted confounders outside this database. However, considering 
the MPR calculation methods that were used (the days supply of medication dispensed 
(excluding the last refill) divided by the number of days between the first and last prescription 
refill) and that the eligible patients in this study came back to their clinics for follow-ups and 
received ≥2 prescriptions, it may still be reasonable to assume that the MPR can detect the 
adherence to chronic medications using prescription data.  
Additionally, there is no detailed dosage information regarding prescriptions in this database. 
Therefore, it is not possible to explore changes in the prescribed dosages of medications. Also, 





Suggestions for Future Studies  
Although this study clarified some possible issues of patient adherence to gout medication 
with a large sample size which can represent the entire U.S. population, there are many data 
limitations because of the database characteristics.  
Additional studies to clarify the relationships between the many possible factors associated 
with gout medication adherence are suggested, especially related to: 1) the financial burden, 2) 
patient education, and 3) physician education. It would be ideal to develop the intervention plans 







Conflicts of Interests 
I, Aki Shiozawa, was a full-time employee of Takeda Pharmaceuticals International, Inc. 
(Deerfield, IL), a manufacturer of Febuxostat in the US, Canada and Mexico when I conducted 
the analysis. Takeda permitted me to access the GE Centricity Electronic Medical Record (EMR) 









1. Gonzalez, E.B., An update on the pathology and clinical management of gouty arthritis. Clin 
Rheumatol, 2012. 31(1): p. 13-21. 
2. Choi, H.K., et al., Pathogenesis of gout. Ann Intern Med, 2005. 143(7): p. 499-516. 
3. Lin, K.C., H.Y. Lin, and P. Chou, The interaction between uric acid level and other risk factors 
on the development of gout among asymptomatic hyperuricemic men in a prospective study. J 
Rheumatol, 2000. 27(6): p. 1501-5. 
4. Campion, E.W., R.J. Glynn, and L.O. DeLabry, Asymptomatic hyperuricemia. Risks and 
consequences in the Normative Aging Study. Am J Med, 1987. 82(3): p. 421-6. 
5. Zhu, Y., B.J. Pandya, and H.K. Choi, Prevalence of gout and hyperuricemia in the US general 
population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum, 
2011. 63(10): p. 3136-41. 
6. Roddy, E., W. Zhang, and M. Doherty, Is gout associated with reduced quality of life? A case-
control study. Rheumatology (Oxford), 2007. 46(9): p. 1441-4. 
7. Singh, J.A. and V. Strand, Gout is associated with more comorbidities, poorer health-related 
quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis, 2008. 67(9): p. 
1310-6. 
8. Lee, S.J., et al., Perceptions of disease and health-related quality of life among patients with gout. 
Rheumatology (Oxford), 2009. 48(5): p. 582-6. 
9. Krishnan, E., et al., Gout and the risk of acute myocardial infarction. Arthritis Rheum, 2006. 
54(8): p. 2688-96. 
10. Choi, H.K. and G. Curhan, Independent impact of gout on mortality and risk for coronary heart 
disease. Circulation, 2007. 116(8): p. 894-900. 
11. Krishnan, E., Gout and the risk for incident heart failure and systolic dysfunction. BMJ Open, 
2012. 2(1): p. e000282. 
12. Park, H., et al., Evaluation of health care costs and utilization patterns for patients with gout. 
Clin Ther, 2012. 34(3): p. 640-52. 
13. Wertheimer, A., R. Morlock, and M.A. Becker, A revised estimate of the burden of illness of 
gout. Curr Ther Res Clin Exp, 2013. 75: p. 1-4. 
14. Khanna, D., et al., 2012 American College of Rheumatology guidelines for management of gout. 
Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to 
hyperuricemia. Arthritis Care Res (Hoboken), 2012. 64(10): p. 1431-46. 
15. Khanna, D., et al., 2012 American College of Rheumatology guidelines for management of gout. 
Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 
(Hoboken), 2012. 64(10): p. 1447-61. 
16. Pandya, B.J., et al., Relationship between physician specialty and allopurinol prescribing 
patterns: a study of patients with gout in managed care settings. Curr Med Res Opin, 2011. 
27(4): p. 737-44. 
17. Sarawate, C.A., et al., Gout medication treatment patterns and adherence to standards of care 
from a managed care perspective. Mayo Clin Proc, 2006. 81(7): p. 925-34. 
18. Becker, M.A., et al., Febuxostat compared with allopurinol in patients with hyperuricemia and 
gout. N Engl J Med, 2005. 353(23): p. 2450-61. 
19. Arellano, F. and J.A. Sacristan, Allopurinol hypersensitivity syndrome: a review. Ann 
Pharmacother, 1993. 27(3): p. 337-43. 
20. Dalbeth, N., et al., Dose adjustment of allopurinol according to creatinine clearance does not 
provide adequate control of hyperuricemia in patients with gout. J Rheumatol, 2006. 33(8): p. 
1646-50. 
21. Becker, M.A., et al., The urate-lowering efficacy and safety of febuxostat in the treatment of the 





22. Schumacher, H.R., Jr., et al., Effects of febuxostat versus allopurinol and placebo in reducing 
serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-
blind, parallel-group trial. Arthritis Rheum, 2008. 59(11): p. 1540-8. 
23. Becker, M.A., et al., Clinical efficacy and safety of successful longterm urate lowering with 
febuxostat or allopurinol in subjects with gout. J Rheumatol, 2009. 36(6): p. 1273-82. 
24. Edwards, N.L., Febuxostat: a new treatment for hyperuricaemia in gout. Rheumatology 
(Oxford), 2009. 48 Suppl 2: p. ii15-ii19. 
25. Khanna, P.P., et al., Health-related quality of life and treatment satisfaction in patients with gout: 
results from a cross-sectional study in a managed care setting. Patient Prefer Adherence, 2015. 9: 
p. 971-81. 
26. Reach, G., Treatment adherence in patients with gout. Joint Bone Spine, 2011. 78(5): p. 456-459. 
27. Riedel, A.A., et al., Compliance with allopurinol therapy among managed care enrollees with 
gout: a retrospective analysis of administrative claims. J Rheumatol, 2004. 31(8): p. 1575-81. 
28. Karve, S., et al., Good and poor adherence: optimal cut-point for adherence measures using 
administrative claims data. Current Medical Research and Opinion, 2009. 25(9): p. 2303-2310. 
29. Leppee, M., et al., Pharmacy claims data as a tool to measure adherence. Current Medical 
Research and Opinion, 2012. 28(8): p. 1389-1393. 
30. Briesacher, B.A., et al., Comparison of drug adherence rates among patients with seven different 
medical conditions. Pharmacotherapy, 2008. 28(4): p. 437-43. 
31. Harrold, L.R., et al., Adherence with urate-lowering therapies for the treatment of gout. Arthritis 
Res Ther, 2009. 11(2): p. R46. 
32. Solomon, D.H., et al., Uric acid lowering therapy: prescribing patterns in a large cohort of older 
adults. Ann Rheum Dis, 2008. 67(5): p. 609-13. 
33. Halpern, R., et al., Impact of noncompliance with urate-lowering drug on serum urate and gout-
related healthcare costs: administrative claims analysis. Curr Med Res Opin, 2009. 25(7): p. 
1711-9. 
34. Zandman-Goddard, G., et al., Rates of adherence and persistence with allopurinol therapy among 
gout patients in Israel. Rheumatology (Oxford), 2013. 52(6): p. 1126-31. 
35. Becker, M.A., et al., Determinants of the clinical outcomes of gout during the first year of urate-
lowering therapy. Nucleosides Nucleotides Nucleic Acids, 2008. 27(6): p. 585-91. 
36. Oderda, G.M., et al., Physician adherence to ACR gout treatment guidelines: perception versus 
practice. Postgrad Med, 2014. 126(3): p. 257-67. 
37. Murray, M.D., et al., A conceptual framework to study medication adherence in older adults. Am 
J Geriatr Pharmacother, 2004. 2(1): p. 36-43. 
38. Crawford, A.G., et al., Comparison of GE Centricity Electronic Medical Record database and 
National Ambulatory Medical Care Survey findings on the prevalence of major conditions in the 
United States. Popul Health Manag, 2010. 13(3): p. 139-50. 
39. DHHS regulations 45 CFR 46.102. U.S. Department of Health & Human Services, 2009. 
40. Andrade, S.E., et al., Methods for evaluation of medication adherence and persistence using 
automated databases. Pharmacoepidemiol Drug Saf, 2006. 15(8): p. 565-74; discussion 575-7. 
41. Cramer, J.A., et al., Medication compliance and persistence: terminology and definitions. Value 
Health, 2008. 11(1): p. 44-7. 
42. Sharabiani, M.T., P. Aylin, and A. Bottle, Systematic review of comorbidity indices for 
administrative data. Med Care, 2012. 50(12): p. 1109-18. 
43. Lachin, J.M., Biostatistical Methods: The Assessment of Relative Risks. . Wiley and Sons, New 
York 2000. 
44. Gupta, D.M., R.J. Boland, Jr., and D.C. Aron, The physician's experience of changing clinical 
practice: a struggle to unlearn. Implement Sci, 2017. 12(1): p. 28. 
45. Schulman, K., Clinical & economic outcomes in patients with a history of chronic kidney disease 
& gout initiating therapy with allopurinol or febuxostat. Data on file. Deerfield, IL: TAP 





46. Shoji, A., H. Yamanaka, and N. Kamatani, A retrospective study of the relationship between 
serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent 
gouty arthritis with antihyperuricemic therapy. Arthritis & Rheumatism-Arthritis Care & 
Research, 2004. 51(3): p. 321-325. 
47. HealthWell Foundation Gout - Medicare Access. 
https://www.healthwellfoundation.org/fund/gout-medicare-access/. 
48. Spencer, K., A. Carr, and M. Doherty, Patient and provider barriers to effective management of 
gout in general practice: a qualitative study. Annals of the Rheumatic Diseases, 2012. 71(9): p. 
1490-1495. 
49. Coburn, B.W., et al., Target Serum Urate: Do Gout Patients Know Their Goal? Arthritis Care & 
Research, 2016. 68(7): p. 1028-1035. 
50. Rees, F., W. Jenkins, and M. Doherty, Patients with gout adhere to curative treatment if informed 
appropriately: proof-of-concept observational study. Annals of the Rheumatic Diseases, 2013. 
72(6): p. 826-830. 
51. Nguyen, A.D., et al., Mobile applications to enhance self-management of gout. International 
Journal of Medical Informatics, 2016. 94: p. 67-74. 
52. Doherty, M., et al., Gout: why is this curable disease so seldom cured? Annals of the Rheumatic 
Diseases, 2012. 71(11): p. 1765-1770. 
53. Tamblyn, R., et al., The incidence and determinants of primary nonadherence with prescribed 










Appendix B: Summary of Literature Review 
 
Author Data Source Number of 
patients
Study population Outcome Covariates MPR>80% Findings Note
Briesacher et al. (2008) Health care claims 
data
9715 US population
>18 year old patients who had diagnosis 
of gout during study period 2001-2004
MPR age, sex, geographic 
residence, history of drug,
type of health plan, and a 
comorbidity score calculated 
by using the Hierarchical 
Condition
Categories risk adjuster
36.80% MPRs increased with increasing 
comorbidities and ages.
History of drug use, health plan, the 
subject’s geographic
area of residence, or Sex did not 
influence adherence.
Comparison of drug adherence among 
patients with 7 different conditions.
No Lab data
Riedel et al. (2004) Administrative claims 
database
5597 US population
Gout patients who filed at least 2 
allopurinol prescriptions. Subjects 
identified from 1997-1998
MPR (They don't use the 
name of MPR, but concept is 
same. "Compliance rate = 
days supply from 1st 
prescription filled / [fill date 
of 2nd
prescription filled – fill date 
of 1st prescription filled")
sex, age, prescription filled, 
comoribidity (diabetes, 
hypertension, Renal failure, 
Obesity, RA, Depression, OA)
18% Sex (female has better compliance), 
Age, Diabetes and hypertension are 
associated with increased 
compliance.
No Lab data
Sarawate et al. (2006) A southeastern US 
health plan database 
(regional DB)
2405 US population 
>18 year old gout patients taking 
allopurinol. Data from 1999-2002
MPR age, sex, preindex 
comorbidities, newly or 
previously diagnosed
gout, and gout flare before 
postindex serum urate
testing
26% Patients with a gout flare before 
postindex serum urate
testing were 50% less likely to be 
compliant.
Patients with baseline
hypertension were 44% more likely 
to be compliant.
No Lab data
Harrold et al. (2008) The healthcare 
deliversy system 
database of two 
systems are located in 
the Northeast and 
Rocky Mountain 
regions of the USA
4166 US population 
>18 year old gout patients taking 
allopurinol. Data from 2000-2006
MPR demographic
age, sex, health care 
utilization (visits to 
providers
for gout both prior to and 
after ULD initiation, all 
provider visits
prior to ULD initiation, and 
number of hospitalizations 
prior to
ULD initiation), specific 
comorbidities, medications.
44% Predictors of poor adherence 
included younger age,
fewer comorbid conditions , no
provider visits for gout prior to 
urate-lowering drug initiation , and 
use of NSAID  prior to urate-
lowering drug initiation
No Lab data
Solomon et al. (2008) US Medicare system
and a pharmacy 
benefit for older low-
income adults
in the state of 
Pennsylvania, the 
Pharmacy
Assistance Contract for 
the Elderly (PACE).
9823 US population 
>65 year old patients enrolled in 
pharmacy benefit program
percentage of
days covered (PDC),a 
measure almost identical to
the Medication Possession 
Ratio (MPR)
Calculated as the days with 
available UALT divided
by the total number of days 
of follow-up
age, gender, race), medical 
care intensity (number of 
physician visits, number of 
different medications used, 
number of acute care 
hospitalisations), comorbid 
conditions, gout specific
factors (the number of acute 
gout arthritis diagnoses; a 
diagnoses of nephrolithiasis; 
a diagnosis of tophi; a 
diagnosis of interstitial 
nephritis; the use of 
selective or non-selective  
NSAID, colchicine, or 




36% Predictors of poor adherence 
included younger age,  
African–American race and 
prescription from non-specialist 
physicians.
No Lab data
Halpern et al. (2009) Administrative claims 
database
10,070 US population 
>18 year old gout patients
MPR sUA 44% Compliance was positively 
associated with favorable sUA in 
unadjusted comparisons.
Lab data (sUA only) - no other covariates





>25 years patients with the diagnosis of 
gout treated with allopurinol identified 
over a 7-year period (2002-2009)
Proportion of days covered 
(PDC), a measure almost 
identical to
the MPR
age, sex, marital status, 
place of residency, years of 
stay in Israel, socio-
economic level, chronic 
conditions, BMI, smoking
17% Women aged 45-64 years, non-
married individuals, those of low
socioeconomic status and those 
with lower BMI were more likely to 
discontinue therapy.
Better compliance was achieved 
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